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Abstract 
Existing research into clinically significant bleeding in Pediatric Intensive Care 
Unit (PICU) patients is limited to specific bleeding sites and specific patient 
groups. Existing literature does not accurately describe the epidemiology of 
clinically significant bleeding in the PICU and may not correctly identify potential 
risk markers. Using a broadly inclusive definition of clinically significant bleeding, 
we conducted a retrospective cohort study of PICU patients and identified clinical 
risk markers including mechanical ventilation, antibiotic and antacid medications, 
performance of multiple procedures, and cardiac surgery. A threshold for platelet 
count associated with clinically significant bleeding in PICU patients was also 
identified, but other common laboratory tests of hemostasis had no association . 
We designed a prospective observational cohort study to further examine the 
association of laboratory tests with clinically significant bleeding. Platelet count 
was again associated with clinically significant bleeding, but the International 
Normalized Ratio (INR) and the activated Partial Thromboplastin Time (PTT) 
were not. This association was present even after adjustment for potentially 
confounding clinical variables. These results suggest that thrombocytopenia is 
an important and potentially modifiable risk factor for clinical significant bleeding 
in PICU patients. 
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Chapter 1: Introduction and Overview 
1.1 Introduction 
Bleeding is a potential danger for critically ill patients, such as those in the 
pediatric intensive care unit (PICU), who have a variety of underlying medical and 
surgical conditions. Uncontrolled hemorrhage can have significant 
consequences for patients, such as organ dysfunction, hypotension, and even 
death. Bleeding, when it occurs, can also have significant implications for patient 
management, including the use of blood products and medications, surgical 
management of bleeding , and delays in required investigations and treatments. 
However, despite the potential importance of bleeding in the PICU , the 
epidemiology of this problem has not been adequately described in the literature. 
Tools for the identification of PICU patients at risk of significant bleeding are not 
available . Although there are a variety of medical therapies available for the 
prevention and treatment of bleeding (platelet concentrates, vitamin K, fresh 
frozen plasma, cryoprecipitate, tranexamic acid , aminocaproic acid , and 
recombinant activated human factor VII), optimal evidence-based strategies for 
the use of these therapies are not known. 
1.2 Definition of Clinically Significant Bleeding 
Not all bleeding presents a danger to the patient or requires intervention. 
Minor bleeding from venipuncture sites, small abrasions and lacerations in 
trauma patients, and trivial bleeding into surgical dressings are all examples of 
bleeding that is not clinically important. Studies that examine bleeding in PICU 
patients, then, must be careful to define bleeding that is considered clinically 
significant. 
Significant or excessive bleeding in PICU patients or post-surgical 
pediatric patients has been defined using a variety of criteria. In pediatric cardiac 
surgery patients, the volume of post-operative chest tube drainage, which can be 
directly measured, has been used to classify bleeding, with significant blood loss 
being defined as post-operative chest tube drainage greater than 20% of 
estimated blood volume (EBV) during the first 2 hours in the PICU , greater than 
20% of EBV during the interval between hours 2 and 6 in the PICU , or greater 
than 30% of EBV during the interval between hours 6 and 12 in the PICU(1 ,2). 
Bleeding that results in changes in clinical management has also been 
classified as significant, including: bleeding requiring medical or surgical 
intervention(3); and severe post-operative bleeding requiring re-operation or 
moderate bleeding causing loss of 1 0 - 20% of estimated blood volume or 
requiring readmission to hospital for intravenous fluids and observation(4 ). 
Some studies have combined some of the above categories of information 
with results of laboratory tests and clinical observations of patients to define 
significant bleeding. These composite definitions of significant bleeding include: 
overt gastrointestinal bleeding plus either a decrease in systolic blood pressure of 
at least 20 mmHg from baseline, an increase in heart rate of at least 20 beats per 
minute from baseline, or a decrease in hemoglobin concentration of at least 20 g 
I L from baseline(5); overt gastrointestinal blood loss that, within 48 hours, results 
in a decrease in hemoglobin concentration of 20 g I L, hypotension, red blood cell 
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transfusion, multiple organ system failure, surgical management of the bleeding, 
or death(6); and macroscopic gastrointestinal hemorrhage with hematologic or 
hemodynamic repercussions such as a decrease in hematocrit of more than 15 
percentage points, hypotension, or a need for volume resuscitation, transfusion, 
or pressors(?). 
What is clear from this disparate literature is that there is no consistent 
definition of clinically significant bleeding in the literature. A variety of types of 
information have been used to define clinically significant bleeding , including 
direct measurement of blood loss, the occurrence of specific interventions after 
bleeding , changes in laboratory data, and changes in patient condition. 
Moreover, to date, only bleeding from specific sites, such as chest tubes or the 
gastrointestinal tract, was considered and composite definitions that have been 
used have only involved a few component criteria. 
A broadly-inclusive definition of cl inically significant bleeding , which 
attempts to capture the wide range of possible physiologic effects of bleeding on 
patients, sites of bleeding, and clinical management decisions in response to 
bleeding , has not been used in any study of PICU patients. (Such a broadly-
inclusive composite definition of significant bleeding has successfully been 
applied prospectively to adult intensive care unit patients(8). ) As a result, the 
studies that currently exist do not describe the epidemiology of all significant 
bleeding in the PICU, and therefore may underestimate the frequency of clinically 
significant bleeding in PICU patients. 
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1.3 Incidence of Clinically Significant Bleeding in PICU Patients 
The studies describing the incidence of clinically significant bleeding in a 
general PICU population have only considered gastrointestinal bleeding, and 
have provided estimates of this incidence from 1.6% (95% Cl 0.8% - 2.4%) (6) to 
5.3% (no confidence interval reported) (5). 
Currently available estimates of the incidence of significant hemorrhage in 
PICU patients show considerable variation . Although this may represent different 
incidences in different study populations, or different incidences that result from 
definitions of significant bleeding that vary between studies, it may indicate a poor 
understanding of the basic epidemiology of clinically significant bleeding in the 
PICU. As previously discussed, the existing literature likely underestimates the 
frequency of phenomenon. 
1.4 Timing of Clinically Significant Bleeding After Admission to the PICU 
Few studies have systematically addressed the timing of significant 
bleeding after admission to the PICU and these studies have been limited to 
surgical patients. In one series of patients undergoing surgery for idiopathic 
adolescent scoliosis, hemorrhagic complications requiring intervention did not 
occur more than 7 days after surgery(3). Using a definition of excessive bleeding 
based on chest tube output, 94% of cardiac surgery patients who had excessive 
bleeding did so within 6 hours of admission to the PICU(1 ). 
Existing literature only provides information on the likely timing of 
significant bleeding for patients admitted to the PICU in small subgroups of post-
operative patients. This makes it difficult for the cl inician to determine the time 
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frame after admission during which it is most important to monitor patients for 
bleeding. This situation also makes study of clinically significant bleeding in the 
PICU more difficult, as the time frame during which bleeding events are most 
likely to be observed is unknown. 
1.5 Common Laboratory Tests as Predictors of Clinically Significant 
Bleeding in PICU Patients 
Platelet count, prothrombin time (PT) or international normalized ratio 
(INR), and activated partial thromboplastin time (PTT) are commonly used 
laboratory tests of hemostasis that have been used to attempt to predict bleeding 
in some settings. However, systematic evaluations of the utility of these tests for 
predicting bleeding risk in general populations of PICU patients are limited. 
In a prospective study of central venous catheter placement in PICU 
patients, patients were described as having a "bleeding diathesis" based on cut-
off values that appear to have been chosen arbitrarily: patients who had platelets 
<50, PT > 20 s, or PTT > 40 s were said to have a "severe diathesis"; and 
patients who had platelets between 50 and 100, PT between 17 s and 20 s, or 
PTT between 35 sand 40 s were said to have a "mild diathesis". (According to 
these definitions, 21% of patients had a bleeding diathesis.) There were 369 
catheter placements and no episodes of clinically significant bleeding occurred in 
any patient, with or without a bleeding diathesis, indicating that this definition of 
bleeding diathesis based on commonly-used laboratory tests had poor predictive 
ability for significant bleeding(9). 
In another study of PICU patients, thrombocytopenia (platelet count < 1 00) 
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was a risk factor for significant gastrointestinal hemorrhage using a univariate 
analysis, but not using a multivariate analysis(5). "Coagulopathy", defined as a 
platelet count less than 100 or PT, PTT, or thrombin time greater than 20% above 
a control value, was associated with an increased risk of clinically significant 
upper Gl bleeding in PICU patients(6). In these studies, the cut-off values used 
to identify patients who may have impaired hemostasis do not appear to have 
been evidence-based. 
The small number of studies that examine the ability of platelet count, 
PT/INR, and PTT to predict clinically significant bleeding in PICU patients provide 
conflicting results, and do not convincingly demonstrate that these tests have a 
role in identifying patients with increased bleeding risk. This could be due, in 
part, to the fact that not all forms of bleeding were considered by these studies. If 
bleeding other than gastrointestinal bleeding had been considered, more 
bleeding events would likely have been observed, and it might have been 
possible to demonstrate associations between bleeding and laboratory tests that 
met criteria for statistical significance. 
Alternatively, it may be that these laboratory tests do not predict bleeding 
risk. In pediatric patients undergoing tonsillectomy/adenoidectomy, the inability 
of PT/INR and PTT to identify patients with increased risk of post-operative 
bleeding has been established, as abnormalities of these tests have been shown 
to have poor sensitivity and positive predictive value for bleeding(4 , 10,11 ). 
Although this patient group differs from PICU patients in many important 
respects , it is still a population subject to a risk of clinically significant 
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hemorrhage. These studies therefore cast considerable doubt on the use of 
PT/INR and PTT as measures of global hemostatic function or as indicators of 
bleeding risk in pediatric patients. However, the limitations of existing studies of 
PICU patients and the potential importance of being able to reliably identify 
patients with increased bleeding risk indicate that this area is in need of further 
study. 
1.6 Clinical Factors as Predictors of Clinically Significant Bleeding in PICU 
Patients 
Some studies have looked at the bleeding risk associated with patient 
characteristics or with aspects of a patient's clinical condition or management in 
the PICU . A series of pediatric cardiac surgery patients found that post-operative 
chest tube output was associated more strongly with age than with any laboratory 
test(2). Another study of pediatric cardiac surgery patients found that patient 
weight of less than 8 kg was associated with increased post-operative chest tube 
output(12). 
A study of PICU patients found that mechanical ventilation was a risk 
factor for significant gastrointestinal bleeding and that prophylactic ranitidine (an 
antacid medication) did not decrease the frequency of significant bleeding. The 
authors speculate that the high frequency of dengue hemorrhagic fever in their 
patients may have reduced the effectiveness of antacid prophylaxis, meaning that 
these results may not be generalizable to other settings(5). 
Another study found that univariate pred ictors of clinically significant 
gastrointestinal bleeding in PICU patients included intubation , mechanical 
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ventilation, acute respiratory distress syndrome, gastric tube placement, enteral 
feeding , organ system failure , and high PRISM score. (The Pediatric Risk of 
Mortality score is a validated tool for predicting mortality in PICU patients.) Other 
predictive variables were antacid prophylaxis, which was associated with 
increased risk, and surgical procedures, which were associated with decreased 
risk. (These two findings, in particular, are counter-intuitive. ) Multivariate 
analysis found that respiratory failure, coagulopathy, and PRISM equal to or 
greater than 10 were the only independent risk factors, and that risk of significant 
bleeding was 18.8% in those patients with all three risk factors(6). 
The literature shows that clinical factors , such as patient age and weight, 
intubation and ventilation, use of prophylactic antacid medication , surgical 
procedures, and family history of bleeding , may have some predictive value. 
Furthermore, in one study the value of clinica l data was greatest when combined 
with laboratory evidence of decreased hemostatic potential. These findings 
suggest that clinical data should be included in any attempt to identify factors 
associated with increased risk of clinically significant bleeding . 
1.7 Summary and Research Plan 
The existing literature describing clinically significant bleeding in the PICU 
is limited in important respects . The epidemiology of cl inically significant bleeding 
and its sequelae are poorly described. Although there are common laboratory 
tests that evaluate some parts of the hemostatic system, they have not been 
convincingly demonstrated to predict bleeding risk for PICU patients. Improved 
understanding of the predictive abil ity of these tests, or the lack of this ability, 
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would be desirable. 
We hypothesized, then , that applying a broadly-inclusive definition of 
clinically significant bleeding to PICU patients would demonstrate that clinically 
significant bleeding is more common in this population than is currently thought. 
We further hypothesized that the number of bleeding events identified with this 
definition would be sufficient to identify and evaluate possible risk markers-
including clinical and laboratory data -for clinically significant bleeding in PICU 
patients. 
In order to test these hypotheses, we conducted a pilot retrospective 
cohort study that was followed by a prospective observational cohort study of 
PICU patients at a single institution. 
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Chapter 2: A Retrospective Cohort Study of Risk Markers for Clinically 
Significant Bleeding in the Pediatric Intensive Care Unit 
This material is adapted from a publication, "An evidence-based threshold for 
thrombocytopenia associated with clinically significant bleeding in pediatric 
intensive care unit patients", in Pediatric Critical Care Medicine 2012 
Sep;13(5):e316-22, and is reproduced here with permission from Wolters Kluwer 
Health (license number 2964750909576). 
2.1 Introduction 
Significant or excessive bleeding is of particular concern for critical ly ill 
patients, and can have serious consequences such as organ dysfunction and 
death. Despite the potential morbidity of significant bleeding for patients in the 
pediatric intensive care unit (PICU), existing research on such bleeding in PICU 
patients is limited. Studies are restricted to particular patient groups (e.g. cardiac 
surgery patients(1 ,2, 12)) or to particular sites of bleeding (e.g. chest tube(1 ,2, 12) 
or gastrointestinal tract( 5-7)). Consequently, existing studies of the epidemiology 
and potential risk factors for clinically significant bleeding in PICU patients may 
not accurately describe all bleeding in an unrestricted population of PICU 
patients. 
We hypothesized that applying a broadly-inclusive composite definition of 
clinically significant bleeding to an unrestricted population of PICU patients would 
demonstrate a higher incidence of cl inically significant bleeding than had 
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previously been observed . We conducted a retrospective cohort study to 
examine the incidence and timing of clinically significant bleeding and to identify 
possible risk factors . 
2.2 Methodology 
This retrospective cohort study took place at the Children's Hospital of 
Eastern Ontario (CHEO), a university-associated pediatric tertiary care centre 
servicing a population of approximately 1.5 million. The CHEO PICU is a 10 bed 
unit that admits approximately 600 patients per year, including post-operative 
cardiovascular surgery patients. The average length of stay in th is unit is 3.9 
days; 57.4% of admitted patients are ventilated; the average Pediatric Risk of 
Mortality (PRISM) score for admitted patients is 5, and the mortality rate is 3.1% 
(CHEO PICU database). This study was approved by the Research Ethics Board 
at CHEO. 
Standardized case report forms (Appendix 1) with instructions (Appendix 
2) were developed, and a research assistant was trained in their use. 
Throughout the data collection , there were frequent meetings between the 
principal investigator and research assistant to discuss data abstraction and 
coding . 
Electronic medical records were used to identify all patients admitted to the 
PICU between January 1st 2009 and June 301h 2009, inclusive. Patients 18 years 
of age and older were outside the pediatric age group, and were excluded . It is 
possible that newborns would need to be studied separately because of their age 
and size. Furthermore, there are significant differences in coagulation factor 
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levels between older children and newborns, and these differences are present at 
least until 30 days of age(13)(14 ). For these reasons, patients less than 60 days 
of age or weighing less than 5 kg were excluded. Other exclusion criteria were 
admission to the PICU because of bleeding, presence of a previously diagnosed 
inherited bleeding disorder, and prior eligible admission to the PICU during the 
study period . Patients who did not meet any exclusion criteria were eligible for 
further data collection. 
Both paper and electronic records of el igible patients were examined . 
Baseline data from the time period beginning 24 hours prior to admission and 
ending 6 hours after admission (an arbitrarily-chosen time point, by which time it 
was assumed that the initial workup of the patient on admission to the PICU 
would have been completed ) were collected . These data included: demographic 
information, including gender, age, weight, and reason for PICU admission; 
clinical information, including vital signs, oral intake, need for respiratory support, 
use of medications (antibiotics, steroids, antacids, anti-hemostatics, pro-
hemostatics), use of blood products, and procedures performed; and laboratory 
information, including complete blood count, transaminases, renal function tests, 
blood gases, and coagulation tests (PTT and INR). If a blood test was performed 
multiple times for one patient, only the resu lt from the time closest to the time of 
admission was collected. Results and events that occurred after an episode of 
clinically significant bleeding (defined below) were not included in the data 
collection or subsequent analysis. 
Patients were assumed to have received standard care and monitoring 
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during their PICU admissions. This would have included routine clinical 
monitoring for bleeding from the mouth, nose, and rectum, as well as bleeding 
from surgical and other wounds, gastric tubes, endotracheal tubes, chest tubes, 
and urinary catheters. Imaging studies and other tests to detect bleeding at other 
sites would have been performed at the discretion of treating clinicians. All 
available records , including notes from physicians, nurses, and other clinicians, 
from the first 7 chronologie days of each eligible PICU admission were examined 
for evidence of clinically significant bleeding. 
Clinically significant bleeding was defined as any blood loss or hematoma 
formation to which the available documentation attributed any of the signs, 
symptoms, or interventions listed in Box 2.1. These criteria were originally 
drafted by the principal investigator and the final revised list was developed in 
consultation with the two senior authors. The principle guiding this definition is 
that bleeding was considered clinically significant either if it had deleterious 
effects on the patient (eg . hypotension or death) or if it prompted an unplanned 
and non-trivial change in management of the patient (eg . transfusion of blood 
products, use of medications such as antacids to control bleeding, or non-trivial 
dressing changes or other procedures to control bleeding), without attempting to 
differentiate clinically significant bleeding of differing levels of severity. 
Records were examined until the occurrence of an episode of clinically 
significant bleeding, discharge from the PICU, or death, whichever came first. 
Details of the event and its management were recorded for each episode of 
clinically significant bleeding observed . The time of an episode of cl inically 
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significant bleeding was taken from the documentation describing the episode; if 
no time was documented for the episode, the time of the documentation itself 
was assumed to be the time of the episode. 
Approximately 10% of charts were randomly selected for independent data 
abstraction to assess the rel iability of data abstraction . Due to the nature of the 
primary outcome event, it was not possible to blind the assessors to the purpose 
of the chart review. Charts were examined for evidence of clinically significant 
bleeding after other data were collected . 
Summary statistics were used to describe the demographic and clinical 
characteristics of patients eligible for this study. Continuous variables were 
summarized using the mean, median, range, standard deviation, and inter-
quartile range. Discrete variables were summarized using frequencies and 
percentages. The incidence of clinically significant bleeding was determined and 
a confidence interval (CI) was computed using the Wilson score method. 
Univariate and multivariate logistic regression were used to calculate odds ratios 
(OR) and 95% Cis for factors associated with increased risk of clinically 
significant bleeding. In addition , recursive partitioning, a multivariable technique 
in which individuals are iteratively separated into groups that are as 
homogeneous as possible with respect to outcome, was used to classify patients 
according to bleeding risk. A Kaplan-Meier curve was used to describe the 
cumulative proportion of patients free of clinically significant bleeding over time. 
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Box 2.1: Definition of Clinically Significant Bleeding 
Clinically Significant Bleeding occurred if blood loss or hematoma formation was 
observed clinically or with imaging, if this blood loss or hematoma formation was 
documented in the patient's medical records, and if there was documented 
attribution to the blood loss or hematoma formation of any of the symptoms, 
signs, or interventions listed below: 
• Death 
• Systolic hypotensiona 
• Decrease in hemoglobin concentration of at least 20 g I L from baseline 
• Organ dysfunction in any organ system 
• Significant symptoms from any organ system 
• Cardiopulmonary resuscitation 
• Surgical or procedural management of blood loss 
• Treatment with volume expanders in volumes of at least 20 ml I kg 
• Transfusion of packed red blood cells in any volume 
• Use of blood products or medication to control bleeding 
• Cessation of anticoagulant medications 
• Surgical or procedural investigation of blood loss 
• Delay or cancellation of an essential intervention or procedure 
• Major revision or reinforcement of a surgical dressing or other dressing 
a Systolic hypotension was defined as systolic blood pressure less than 90 mmHg 
for patients aged 10 years or more, less than 70 + 2 x (age in years) mmHg for 
patients aged 1 year or more but less than 10 years, and less than 70 mmHg for 
patients aged less than 1 year 
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2.3 Results 
There were 326 admissions to the PICU during the study period, and 214 
were included. The number of patients meeting each exclusion criterion is 
summarized in Figure 2.1. 
Of those 214 eligible admissions, 114 (53.5%) were female . The mean 
age of included patients was 7.9 years (standard deviation 6.0 years) . 94 
patients (43.9%) were admitted due to surgery, 118 (55.1 %) due to medical 
conditions, and 2 (0.9%) due to trauma. 
There was complete agreement regarding the inclusion and exclusion of 
admissions (kappa = 1.0), but poor agreement regarding the occurrence of 
clinically significant bleeding (kappa = 0.26). Consequently, records from all 
eligible admissions were independently examined by the principal investigator for 
the occurrence of clinically significant bleeding. Disagreements between the 
research assistant and principal investigator about whether an episode of 
clinically significant bleeding had occurred were resolved by one of the senior 
investigators through examination of patient records and application of the 
definition in Box 2.1 . Episodes of clinically significant bleeding are summarized in 
Table 2.1 . 
17 
Figure 2.1: Patients and Outcomes 
I Admissions to PICU (n = 326) I 
Excluded admissions (n = 112'') 
. Admitted due to bleeding (n = 22) 
. Inherited bleeding disorder (n = 1) 
. Weight < 5 kg (n =50) 
. Age < 60 days or;?: 18 years (n = 36) 
. Prior inclusion (n = 38} 
I El igible admissions (n = 214) I 
1 1 1 1 
Clinically Discharged Duration of Died 
Significant from PICU Adm ission 
Bleed ing > 7 days 
(n = 19) (n = 179) (n = 12) (n = 4) 
a Some patients met more than one exclusion criterion. 
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Patient outcomes are shown in Figure 2. 1. The incidence of clinically 
significant bleeding was 8.9% (19 episodes among 214 eligible patients, 95% Cl 
= [5 .8%, 13.4%]). Details of these episodes are shown in Table 1. For those 
patients who experienced an episode of clinically significant bleeding , the median 
time from admission to the PICU to bleeding event was 9.8 hours (range= [0.5 h, 
137.8 h], interquartile range= [4.1 h, 31 .6 h]). A Kaplan-Meier analysis of time-
to-bleeding-event is shown in Figure 2.3; in this analysis, episodes of cl inically 
significant bleeding were outcome events, and discharge from the PICU and 
death were censoring events. 
A summary of univariate analysis of factors that were considered to be 
possibly associated with clinically significant bleeding is shown in Table 2.2. 
Thrombocytopenia (platelet count < 100 x 109 I L, threshold determined from 
patient data by a recursive partitioning algorithm) was significantly associated 
with increased odds of clinically significant bleeding. Platelet count was 
measured in 15 of 19 patients who had clinically significant bleeding, and in 161 
of 214 patients overall. Mean platelet counts in the group of patients with 
clinically significant bleeding (211 x 109 I L, standard deviation 111 x 109 I L) and 
without (301 x 109 I L, standard deviation 155 x 109 I L) were significantly different 
(p = 0.03). 
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Table 2.1: Summary of Clinically Significant Bleeding Events 
M, male . F, female . y, year. m, month. hr, hour. PICU , Pediatric Intensive Care 
Unit. PRBCs, Packed Red Blood Cells. FFP, Fresh Frozen Plasma. VSD, 
Ventricular Septal Defect. NG, Nasogastric tube. G-tube, gastrostomy tube. 
ECMO, Extracorporeal Membrane Oxygenation . CT, x-ray Computed 
Tomography. EVD, External Ventricular Drain . 
a These patients had two different forms of bleeding , both judged to be cl inically 
significant, documented simultaneously in their medical records. 
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Gender Age Reason for Admission Time from Admission Observation of Bleeding Criteria tor 
to PICU to Bleeding Clinica lly Significant Bleeding 
M 15 y 2m Congestive heart fai lure 118.5 hr bleeding at femoral arteria l line site · revision of line dressing 
bloody chest tube output 0 transfusion of PRBCs, p l atele~ FFP 
F 5m Post-op VSD repa ir 3.6 hr bloody chest tube out put t ransfusion of PRBCs, cryoprecipitate, 
FFP 
M 8m Post-op VSD repair 22.5 hr bloody chest tube output transfusion of PRBCs 
M 10m Post -op Glen 7.0 hr nose bleed epinephrine mask given 
F 7m Seizures 3.8 hr blood in NG aspirates ranit idine given 
F 4 y 7 m Post-op Fonta n 3.4 hr bloody chest tube output hypotension 
transfusion of platelets, 
cryoprecipitate, albumin S% 
M 4y 11m Pneumonia 30.0 hr blood suctioned from mouth and nose, ranitidine given 
and vent ed from G-tube 
7m Bronchiol itis 9.6 hr bloody vomit us NG tube placed 
10m Bronchioli tis 73.6 hr bloody discharge with removal of NG ranitidine £iven 
NF 13 y 1 m Seizures 4.1 hr blood from NG t ube t ransfusion of platelets 
stopped NG clobazam 
F 5m Post-op Glen 33.2 hr bloody chest tube output transfusion of PRBCs 
decrease in hemoglobin .by 40 g I L 
F 9y4 m Post-op craniotomy 23.9 hr bleeding th rough surgica l dressing decrease in hemoglobin by 25 g I L 
M 7y 3m ~esRirator failure 20.8 hr bleeding from ECMO catheter site revision of catheter dressing 
M 5m Post-op complex 137.8 hr bleeding from central line site revision of central line dressing 
card iovascular su rgery 
F 4y9 m Post-op aortic stenosis 9.8 hr bloody chest tube output decrease in hemoglobin by 47 gI L 
repair bloody NG aspirate0 t ransfusion of PRBCs, albumin 5% 
ranitidine given 
M 11 y 1m Brain tumor 42.5 hr bleeding from surgica l site revision of surgical dressing 
M 3 y7 m Post-op VSD repair 4.1 hr bloody chest tube output use of volume expanders (normal 
saline and albumin· 5%) 
F 14 y 0 m Post-op Ladd 0.5 hr surgica l dressing soaked with blood revision of surgical dressing 
M 6 y 1Q m Post-op craniotomy and 4.5 hr post-surgical hematoma on head CT caused abnormal facia l· movements 
• ,. <" 
tumour res~ction craniotomy and EVD placed 
Figure 2.2: Kaplan-Meier Analysis of Time to Clinically Significant Bleeding 
Event. 
Discharge from the Pediatric Intensive Care Unit (PICU) and death were treated 
as censoring events, as were stays in the PICU longer than 7 chronological days 
after admission. The inset figure shows more detail regarding the first 48 hours 
after admission. Pointwise 95% confidence intervals are shown in grey. 
22 
Inset 
1.0 
' 
'I .. 
" 
0.8 
Ol 
c 
-a 
Ill 
Ill 
:0 
c 
Cll 
ll 
~ 0.6 
c 
.Ql 
rn 
2=-
Cll 1.00 -~ 
c 
(3 
0 
Ill 0.4 ~ 0 .95 
c 
0 
:;:: 
0 
0. 
e 
11.. 0.90 
0 .2 
0.85 
0.0 0 .5 1.0 1.5 2.0 
0.0 
0 2 3 4 5 6 7 
Time (days) 
23 
Mechanical venti lation, use of antibiotic and antacid medications, and 
performance of multiple (3 or more) procedures were among factors that were 
associated with increased risk as wel l. Use of antihemostatic medications, 
prohemostatic medications, and blood products also had significant positive 
associations with clinically significant bleeding. Use of steroid medication, 
absence of enteral feeding, INR, and PTT did not. 
Given the number of episodes of clinically significant bleeding observed (n 
= 19), and a published rule-of-thumb that one variable may be included in a 
multivariate analysis for every ten outcome events observed(15), two variables 
were chosen for inclusion in a multivariate logistic regression model: mechanical 
ventilation, which has been previously reported as an important risk factor(6)(5), 
and thrombocytopenia, which may be an important modifiable risk factor. Both 
mechanical ventilation (OR 5.6, 95% Cl [1 .7, 18.5]) and thrombocytopenia (OR 
11 .8, 95% Cl [2 .3, 61 .2]) were significant risk markers in this multivariate model 
(Nagelkerke R2 = 0.23). Anti-hemostatic medications were added to this model : 
while they had a significant association with increased risk of clinically significant 
bleeding (OR 4.2, 95% Cl [1.1 , 15.9]) and thrombocytopenia remained 
statistically significant (OR 14.3, 95% Cl [2 .3, 88.0]), mechanical venti lation lost 
its statistical significance (OR 3.4, 95% Cl [0.94, 12.2]) in this model (Nagelkerke 
R2 = 0.29). Neither pro-hemostatic medications nor blood products had 
significant association with bleed ing risk when added singly to the original 
multivariate model. 
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Table 2.2: Univariate Analysis 
Cl , confidence interval. INR, International Normalized Ratio. PTT, activated 
partial thromboplastin time. 
Factor Odds Ratio [95% Cl ) p-value 
Demographic Variables 
Age (per year) 0.92 [0.84, 1.00) 0.05 
Male a 1.29 [0.45, 3.78) 0.64 
Clinical Variab les 
Surgical admission b 1.85 [0.65, 5.55) 0.23 
Cardiac surgery admission c 7.5 [2.3, 23.9] <0.001 
Mechanical ventilation 4.5 [1.6, 13.9] 0.002 
Enteral feed d 1.22 [0.28, 4.14) 0.76 
Multiple procedures e 4.2 [1.4, 15.4] 0.007 
Antibiotic 10.9 [1.7, 463.8] 0.004 
Antacid 3.5 [1.2, 10.3] 0.01 
Steroid 0.28 [0.03, 1.24) 0.11 
Prohemostatic medication 3.3 [1.1, 9.8] 0.03 
Antihemostatic medication 4.5 [1.6, 13.9] 0.002 
Blood product 3.1 [1.0, 9.1] 0.03 
Laboratory Variables 
Platelet count< 100 x 109 / L 12.9 [2.8, 58.8] <0.001 
INR (per unit) 2.2 [0.7, 6.4) 0.15 
PTI(persecond) 1.00 [0 .99, 1.04) 0.34 
Factors with statistically significant associations (p-value < 0.05) are in bold. 
a Compared to female. b Compared to non-surgical admissions. c Compared to 
all other admissions. d Including oral or enteral tube feeds. e 3 or more 
procedures. 
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When evaluated in patients other than those admitted after cardiac 
surgery, thrombocytopenia was no longer a statistically significant risk factor (OR 
5.1, 95% Cl [0.09, 64.0]). There was no interaction between thrombocytopenia 
and admission following cardiac surgery (p = 0.99), and both these factors were 
significant (cardiac surgery: OR 8.0 with 95% Cl [2.4, 26.7], thrombocytopenia: 
OR 11.2 with 95% Cl [2.1 , 60.7]) in a main effects multivariate model (Nagelkerke 
R2 = 0.26). 
Since only 3 patients bled after 48 hours or more, we did not feel that the 
characteristics of such "late bleeders" could be meaningfully analyzed. 
2.4 Discussion 
This is the first study to apply a broadly inclusive definition of clinically 
significant bleeding to a group of PICU patients. Others have reported 
incidences of 1.6%(6) and 5.3%(5) for gastrointestinal tract bleeding in an 
unrestricted PICU patient population. We found that clinically significant bleeding 
was more frequent, with an incidence of 8.9%, than was reported by these other 
studies, likely because of our inclusion of bleeding from all observable sites and 
of any bleeding that either had deleterious effects on the patient or required 
changes in patient management. 
A prior study found that thrombocytopenia (platelet count less than 100 x 
1 09 I L) was associated with significant gastrointestinal hemorrhage in univariate 
analysis, but not in multivariate analysis(5). Another study of PICU patients 
defined "coagulopathy" as the presence of a platelet count less than 100 x 109 I L 
or prothrombin time, PTT, or thrombin time greater than 20% above a control 
26 
value; patients who met this definition of coagulopathy had an increased risk of 
clinically significant upper gastrointestinal tract bleeding(6). Importantly, the cut-
off values for laboratory tests used in these studies do not appear to have been 
evidence-based. 
We found that a platelet count less than 1 00 x 1 09 I L was associated with 
clinically significant bleeding. This threshold value for predicting bleeding risk 
has been used in other studies(5,9), but ours is the first study to identify this 
threshold from patient data. Although a threshold defined from patient data will 
not be subject to the same biases as a threshold defined by expert opinion (eg . 
recall bias), a data set derived over a small period of time at a single institution 
may not produce results that generalize to other settings in which important 
factors (eg . the proportion of patients admitted for cardiac surgery, the frequency 
with which a complete blood count is obtained on admission to the PICU, or 
laboratory instruments) may be different. Furthermore, since we considered only 
values of platelet count collected near the time of admission , it is possible that 
this threshold may not apply to platelet counts measured later during an 
admission. 
Although this threshold was no longer had a statistically significant 
association when patients admitted following cardiac surgery were excluded from 
the analysis, the 95% Cl for the estimated OR was very wide. Therefore, we 
cannot definitively exclude this degree of thrombocytopenia as a risk marker for 
clinically significant bleeding in the subgroup of patients who were not admitted 
following cardiac surgery. A more powerful study will be required to address this. 
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There is literature in the oncology and hematopoietic stem cell 
transplantation populations that examines platelet transfusion thresholds. 
Randomized trials that include some pediatric patients have found no difference 
in bleeding events using a platelet transfusion threshold of 1 0 x 1 09 I L compared 
to one of 20 x 109 I L(16)(17) or 30 x 109 I L(18). However, these are findings in 
very specific patient populations and include adult patients: they are not 
necessarily generalizable to purely pediatric groups or critical care patients. In 
addition, while these studies do demonstrate that the compared thresholds have 
equivalent safety, their findings do not imply that the levels of thrombocytopenia 
considered do not confer a bleeding risk compared to higher platelet counts; nor 
do they exclude the possibility that a higher transfusion threshold than was 
examined might reduce the frequency of bleeding events. Indeed, rates of 
bleeding events in these studies range from 14%(1 7) to 18%(18)(16), which are 
higher than we observed. Our result is therefore not inconsistent with these 
studies. 
The lack of evidence-based thresholds for laboratory tests that are used to 
screen for bleeding risk is one of the major impediments to the development of 
rational strategies for the use of blood product transfusions and other therapies. 
However, it would be premature to suggest that critically ill patients should be 
transfused to maintain a platelet count greater than 100 x 109 I L. Underlying 
conditions may cause thrombocytopenia and independently cause increased 
bleeding risk through other mechanisms (e .g. tissue injury, depletion of 
coagulation factors, decreased platelet function ) that might not be corrected by 
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platelet transfusion. 
The use of blood products, pro-hemostatic medications, and anti-
hemostatic medications were all found to be risk markers in univariate analysis, 
but only anti-hemostatic medications remained significant in multivariate analysis. 
Pro-hemostatic medications and many blood products (eg. platelet concentrates, 
frozen plasma, cryoprecipitate) might be expected to reduce risk, but their use 
may be more common in patients who are likely to bleed. The size of our study 
and the fact that we only considered the use of these medications in a period 
close to the time of admission, as well as the retrospective nature of our study, 
prevent us from determining the true role of these therapeutic agents in modifying 
bleeding risk. 
In contrast to platelet count, INR or PTT were unable to predict bleeding 
risk, as has been previously demonstrated in pediatric patients who have had 
tonsillectomy/adenoidectomy(4, 10,11 , 19). Although this patient group will have 
consisted largely of healthy children who differ from PICU patients in many 
respects - duration of intubation, exposure to medications with possible effects 
on hemostasis, and presence of medical conditions that may result in impaired 
hemostasis - it is still a patient group with a known risk of significant bleeding . In 
this patient group the INR and PTT functioned poorly as predictors of impaired 
hemostasis, which is in agreement with our findings. It is possible that these 
tests were not performed sufficiently often in our study population to detect a 
predictive ability of these tests: platelet count was measured for 161 patients, 
compared to 85 patients for whom INR and PTT were measured. It may also be 
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the case that patients who had abnormal INR or PTT on admission to the PICU 
received treatment to correct these lab values that also decreased bleeding risk. 
Since we collected only the values for INR and PTT obtained closest to time of 
admission, we were unable to look for this possible effect. 
Our observation that mechanical ventilation is a risk factor for clinically 
significant bleeding is consistent with other studies(5,6). The finding that use of 
antibiotic or antacid medications are associated with increased risk of clinically 
significant bleeding may reflect effects of these medications on hemostasis (e.g. 
effect of antibiotics on enteric vitamin K metabolism), or may simply reflect 
bleeding risk conferred by the condition of the patients who received these 
medications. 
Cardiac surgery patients deserve special mention. Eight of 19 episodes of 
clinically significant bleeding occurred in these patients, and the estimated OR for 
this group was 7.5. This is not surprising, given the previous observation of high 
rates of excessive chest tube output in this patient group(1 ). However we found 
that 3 of these 8 patients had clinically significant bleeding at other sites. While 
likely not as serious as blood loss through a chest tube, these other forms of 
bleeding were sufficient to prompt changes in management. Cardiac surgery 
patients should be closely monitored for bleeding at sites other than chest tubes. 
Ours is the first systematic analysis of the timing of clinically significant 
bleeding in a general PICU population . Previously available data are limited to 
surgical patients: patients requiring surgery for idiopathic adolescent scoliosis did 
not have hemorrhagic complications more than 7 days after surgery(3), and 
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cardiac surgery patients who had excessive chest tube output did so within 6 
hours of PICU admission in 94% of cases(1 ). In comparison, we found that more 
than 80% of observed bleeding events occurred within 48 hours of admission to 
the PICU. Patients may be more likely to experience clinically significant 
bleeding early during an admission because of factors related to their acute 
illnesses. In addition , treatment given after admission may rapidly decrease 
bleeding risk. 
Three clinically significant bleeding events were observed in the small 
group of patients who were admitted longer than 48 hours. Although this would 
appear to indicate a substantial risk of bleeding for those patients with prolonged 
admissions, the small patient numbers and wide confidence intervals 
demonstrated in Figure 2 require caution regarding such interpretation. 
Specifically, the use of a Kaplan-Meier curve to describe the timing of clinical ly 
significant bleeding likely includes an element of informative censoring: nearly all 
censoring was because of discharge from the PICU , representing clinical 
improvement that likely indicated decreased bleeding risk for many patients. On 
the other hand, censoring patients at death is problematic: patients who died may 
have deteriorated in ways that might actually have increased bleeding risk, but 
this increased risk would not have been detected. However, it was not possible 
to estimate this increase in risk with the design of our study. 
This study is limited by its retrospective design. In particular, the complex 
composite definition of clinically significant bleeding that we used resulted in 
some difficulty with reliable case finding . This was likely due to the difficulty in 
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ascribing, from chart data only, relevant symptoms or interventions to observed 
bleeding in a causal manner. However, a study of adult Intensive Care Unit 
patients has demonstrated that a definition of significant bleeding similar to ours 
can be reliably applied prospectively(20). Additionally, the time of bleeding was 
not explicitly documented for some patients, and so for these patients the time of 
bleeding was assumed to be the time of the documentation of the bleeding. 
Since an episode of bleeding cannot have occurred after its documentation, we 
may have over-estimated the interval between admission and bleeding in some 
cases. However, because most bleeding events occurred soon after admission, 
the effect of this over-estimation is likely small. Observational studies generally 
cannot establish causation, so the identified risk factors for clinically significant 
bleeding should be regarded only as associated variables, not causative 
influences. Because only one episode of clinically significant bleeding could be 
recorded for each patient, however, the likelihood of spurious associations 
between patient characteristics and clinically significant bleeding is reduced . A 
further limitation of our study is the relatively small number of clinically significant 
bleeding events observed , which limits, in particular, the number of variables 
included in our multivariate logistic regression models. A larger study in which 
more bleeding events were observed or a prospective study in which more 
bleeding events might be captured would provide more detailed multivariate 
analysis. 
32 
2.5 Conclusions 
Clinically significant bleeding is more common in the PICU than has been 
previously reported and the majority of episodes occur in the first 36 hours 
following admission. The threshold for thrombocytopenia associated with 
clinically significant bleeding should be confirmed in a prospective study. Other 
risk markers for clinically significant bleeding include mechanical ventilation, the 
use of antibiotic and antacid medications, and the performance of multiple 
procedures. 
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Chapter 3: A Prospective Study of Common Laboratory Tests of 
Hemostasis as Predictors of Early Clinically Significant Bleeding in the 
Pediatric Intensive Care Unit 
3.1 Introduction 
The pilot retrospective cohort study described in Chapter 2 demonstrated 
that clinically significant bleeding , defined in a broadly inclusive manner, occurred 
more frequently in pediatric intensive care unit (PICU) patients than had 
previously been observed . The large majority of episodes of clinically significant 
bleeding in the PICU occurred during the first 48 hours of admission. Factors 
that were observed to be associated with clinically significant bleeding included 
mechanical ventilation , card iac surgery, and thrombocytopenia (platelet count 
less than 100 X 109 I L). This threshold for platelet count has been used before 
to identify PICU patients presumed to be at increased risk of significant 
bleeding(5,6,9), but ours was the first study to identify this threshold from analysis 
of patient data. Other common tests of hemostasis, INR and PTT, were not able 
to identify patients with increased risk of clinically significant bleeding . However 
these measurements were made for fewer patients than measurements of 
platelet count. Furthermore, in that retrospective study we considered these 
measurements at only one time point, that closest to the time of admission. It is 
possible then that new information about the ability of platelet count, INR, or PTT 
to predict clinically significant bleeding could be derived from a study in which 
more patients were included, more bleeding events were observed , and more 
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measurements of these quantities were included in the analysis. 
We proceeded to a prospective examination of the ability of platelet count, 
INR, and PTT to predict clinically significant bleeding during the first 72 hours of 
admission to the PICU, using the same definition of clinically significant bleeding 
that was used in the pilot retrospective study. Although our broadly inclusive 
definition of clinically significant bleeding was difficult to apply retrospectively, 
resulting in some difficulty with case finding , a similar definition has been 
prospectively applied in adult intensive care unit patients with reliability(20). 
3.2 Methodology 
This was a prospective observational cohort study conducted in the PICU 
at the Children's Hospital of Eastern Ontario (CHEO). CHEO is a university-
affiliated tertiary care children's hospital with a referral population of 
approximately 1.5 million people, and the CHEO PICU has 10 beds and an 
annual average of approximately 600 admissions, including post-operative 
cardiac surgery patients. Patients are admitted for an average of 3.9 days with 
an average Pediatric RISk of Mortality (PRISM) score of 5, and 57.4% are 
mechanically ventilated (CHEO PICU database). This study was approved by 
CHEO's Research Ethics Board. The Research Ethics Board determined that, 
because this was a purely observational study, consent from patients or their 
substitute decision-makers was not required . 
A standardized case report form (Appendix 3) and a standardized 
instruction set for this form (Appendix 4) were developed, and research 
assistants were trained in their use. Throughout the study period, frequent 
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communication, both electronically and in person, occurred between the research 
assistants and the principal investigator to discuss the data collection . 
All patients admitted to the PICU during the study period , from January 4th 
2010 to August 20th 2010, were considered for inclusion in this study. Criteria for 
exclusion were prior inclusion in this study, previous diagnosis of an inherited 
bleeding disorder, admission to the PICU because of bleeding , age at admission 
less than 60 days or greater than or equal to 18 years, and weight at admission 
less than 3 kg . These are the same exclusion criteria that were used in the pilot 
retrospective study, with the exception of the lower limit for weight, which had 
been 5 kg. This change was made because it was felt, after the completion of 
the retrospective study, that some patients had been excluded solely because of 
this higher weight limit but did not have a history of prematurity or other 
characteristics that might have differentiated them from the general study 
population in terms of the risk of serious bleeding such as intracranial 
hemorrhage. 
The paper and electronic medical records of all included patients were 
examined to extract each patient's age, gender, weight, reason for admission, 
and time of admission. Each included patient's admission was divided into 
consecutive 24 hour time periods from 24 hours prior to admission to 72 hours 
after admission , and the following information was extracted for each time period: 
maximum and minimum vital signs (heart rate, respiratory rate, systolic blood 
pressure, oxygen saturation , and temperature); use of supplementary oxygen, 
mechanical ventilation , and enteral or parenteral feeds; medications (antibiotics, 
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antacids, steroids, pro-hemostatics, anti-hemostatics), blood products, and 
procedures. The results of all measurements of platelet count, INR, PTT, and 
plasma fibrinogen concentration , as well as the dates and times of these 
measurements, were recorded . The dates and times of administration of platelet 
concentrates, frozen plasma, cryoprecipitate, and vitamin K were also recorded. 
The primary endpoint for the study was clinically significant bleeding. 
Bleeding was considered to be clinically significant bleeding if and only if it 
satisfied, in the opinion of bedside caregivers, any of the criteria described in Box 
2.1. Blood loss or hematoma formation at any site was considered , with one 
exception: because the retrospective study demonstrated a very high incidence 
of excessive chest tube bleeding among cardiac surgery patients and because 
this form of bleeding was essentially limited exclusively to cardiac surgery 
patients, excessive chest tube bleeding in cardiac surgery patients, while it was 
recorded , was not included in the analysis; bleeding from other sites in cardiac 
surgery patients could be included if it satisfied any of the criteria in Box 2.1. 
In order to detect episodes of clinically significant bleeding, bedside nurses 
and physicians (including trainees such as residents and fellows) in the PICU 
were contacted daily. This communication was usually in the form of visits to the 
PICU , but on the weekends or on holidays it may have taken place over the 
phone. During these communications, these bedside caregivers were asked 
whether patients included in the study had experienced any bleeding or 
hematoma formation . In the event that bleeding or hematoma formation had 
occurred, bedside caregivers were then asked whether the patient satisfied any 
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of the criteria in Box 2.1 . Finally, if any of these criteria were satisfied , bedside 
caregivers were asked if the observed blood loss or hematoma formation was the 
cause of observed signs or symptoms or the reason for any interventions. A 
printed sheet (Appendix 5) was used to identify these criteria for bedside 
caregivers. The time of a clinically significant bleeding event was given by 
bedside caregivers, taken from documentation describing the event, or assumed 
to be the same as the time of the documentation describing the event. 
For reasons of practicality and availability of data collectors, repeated 
independent data collection, for purposes of assessing the reliabi lity of both data 
collection and detection of clinically significant bleeding events, was not done for 
any patients. 
This was a purely observational study, and no specific protocol for clinical, 
laboratory, or radiographic monitoring was required. The study did not mandate 
any interventions for patients who had abnormal blood test results or other 
characteristics that might have been thought to increase bleeding risk. Patients 
were assumed to receive standard care and monitoring in the PICU. 
Interventions were solely at the discretion of bedside caregivers. 
Data collection for each included patient continued until the patient was 
discharged from the PICU or died, or until 72 hours after admission, whichever 
came first. 
Descriptive statistics were used to describe patient demographics and the 
overall incidence of clinically significant bleeding. A Kaplan-Meier curve was 
used to describe time from admission to clinically significant bleeding events. 
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Univariate Cox proportional hazard models were constructed using some 
fixed covariates such as admission diagnosis, and measurements of platelet 
count, INR, PTT, and fibrinogen as time-varying covariates(21 ). The last 
measured value of one of these quantities was used until a new measurement 
was made. In order to include those patients for whom these measurements 
were not available at given time points and to account for the effects of 
transfusion of platelets, frozen plasma, and cryoprecipitate, the Cox proportional 
hazard analysis was repeated , using the following rules to generated imputed 
values of platelet count, INR, PTT, and fibrinogen: (1) Platelet transfusion was 
assumed to raise the platelet count by 50 x 109 I L, following expert opinion in the 
literature(22). (2) Transfusion of frozen plasma was assumed to restore the PTT 
and INR to the upper limit of the age-dependent reference ranges in the CHEO 
laboratory. (There are no algorithms or opinions to estimate the effects of plasma 
transfusion on these parameters.) (3) Transfusion of cryoprecipitate was 
assumed to restore the fibrinogen level to the lower limit of the age-dependent 
reference range in the CHEO laboratory. (Again , no literature describes 
estimated effects of cryoprecipitate transfusion.) (4) If no measurement of 
platelet count, PTT, INR, or fibrinogen had yet been made for a patient, the value 
of that quantity was assumed to be the midpoint of the age-dependent reference 
range for that quantity in the CHEO laboratory. In the case of patients for whom 
a quantity was never measured, this midpoint value is assumed throughout their 
inclusion in the study. This rule is based on an assumption that clinician 
behaviour is informative: if these measurements had not been made before a 
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particular time, treating clinicians likely believed, based on clinical information 
about the patient, that the results of these tests would have been normal. 
Because vitamin K administration does not immediately correct the INR and 
because virtually all patients who received vitamin K had their INR rechecked 
within 24 hours, it was not necessary to use imputed corrections for INR after 
vitamin K administration and the effect of vitamin K was not analyzed. 
In these analyses, censoring patients at discharge from the PICU is likely 
informative: patients who were discharged had clinically improved in ways that, 
in many cases, likely decreased their bleeding risk. In order to explore this 
possible effect, the Cox analyses were done with both this censoring rule and 
without. In the latter analysis, even though no further data were collected on 
patients who had been discharged from the PICU, they were assumed to have no 
bleeding risk after discharge. Deaths were treated as censoring events in both 
analyses. 
3.3 Results 
During the study period, 342 patients were admitted to the PICU . 40 
charts (11 .7%) were selected at random for independent re-entry of data from the 
case report forms to the database. The rate of discrepancies between the two 
data entries was 0.37%, less than the 0.5% that had been pre-determined as the 
maximum acceptable error rate for the data entry. The error rate for data items 
related to the occurrence of bleeding events and to measurements of platelet 
count, INR, PTT, and fibrinogen was 0.1 %. 
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Figure 3.1: Patients and Outcomes 
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The flow of patients through the study is shown in Figure 3.1. Of the 342 
patients admitted to the PICU during the study period, 108 were ineligible: 27 
were admitted to the PICU because of bleeding; 2 had a previously-diagnosed 
inherited bleeding disorder; 13 weighed less than 3 kilograms; 52 were less than 
60 days of age or greater than or equal to 18 years of age; and 29 had been 
included in the study during a prior admission to the PICU . (Some patients met 
more than one exclusion criterion.) The remaining 234 patients were included in 
the study. The numbers of eligible patients still being followed 24, 48, and 72 
hours after admission were 163, 89, and 65, respectively. The cumulative 
number of deaths 24, 48, and 72 hours after admission were 2, 3, and 3, 
respectively. 
109 included patients (46.6%) were female. Median patient age at time of 
admission was 62 months (range 2 to 215 months, inter-quartile range 144 
months), and median patient weight was 18 kilograms (range 3.1 to 1 07 
kilograms, inter-quartile range 37 .5 kilograms). 
5 eligible patients (2.1 %) were admitted to the PICU because of trauma, 
111 (47.4%) were admitted following surgery, and 118 (50.4%) were admitted 
because of medical illnesses. 
Overall , 31 patients (13%) experienced one or more episodes of clinically 
significant bleeding during the first 72 hours of admission to the PICU . 21 
patients had a single episode of clinically significant bleeding, 8 had two 
episodes, and 2 had three episodes. 
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Figure 3.2: Kaplan-Meier Analysis of Time to Clinically Significant Bleeding 
Event. 
95% confidence intervals shown in dashed lines. 
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A Kaplan-Meier analysis of time to clinically significant bleeding event is 
shown in Figure 3.2. 
There were 22 eligible patients in the study who had no laboratory 
evaluation of hemostasis during their inclusion in the study, and none of these 
patients experienced episodes of clinically significant bleeding. This provides 
conceptual validation for the imputation rule that assumed values of INR, PTT, 
and fibrinogen at the mid-point of the age-appropriate normal range for patients 
for whom these measurements had not been made. 
There were 21 patients who received one or more platelet transfusions, 9 
patients who received one or more transfusions of cryoprecipitate, and 11 
patients who received one or more transfusions of FFP. 
In Cox proportional hazard models using platelet count, INR, PTT, and 
fibrinogen as univariate time-varying covariates, with use of the imputation rules 
described above and with discharge treated as a censoring event, only platelet 
count had a statistically significant association with clinically significant bleeding 
(HR = 0.67 per 100 x 109 I L increase in platelet count, 95% Cl = 0.49 - 0.92, p = 
0.01 ). When these analyses were repeated with discharge not considered a 
censoring event and with the assumption that cl inically significant bleeding did 
not occur after discharge, platelet count was again the only parameter with a 
statistically significant association with clinically significant bleeding (HR = 0.66 
per 100 x 109 I L increase, 95% Cl = 0.48- 0.90, p = 0.01 ). 
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Table 3.1: Hazard Ratios for Clinically Significant Bleeding, from a 
Multivariate Model, with and without Censoring at Discharge 
Discharge times treated Discharged patients 
assumed to have no 
as censored observations further bleeding 
Hazard ratio p- Hazard ratio p-
(95% Cl) value (95% Cl) value 
Platelet count 
(per increase by 0.68 (0.49, 0.93) 0.02 0.67 (0.49, 0.92) 0.01 
100 X 1 09 I L) 
INR 
(per increase in 0.96 (0.44, 2.07) 0.92 0.97 (0.47, 2.03) 0.94 
numerical value 
by 1) 
PTT 
(per increase by 1 1.00 (0.98, 1.03) 0.76 1.01 (0.98, 1.03) 0.73 
second) 
Fibrinogen 
(per increase per 1.03 (0.83, 1.27) 0.78 1.04 (0.85, 1.28) 0.70 
1 gIL) 
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Results from Cox proportional hazards models using platelet count, INR, 
PTT, and fibrinogen as multiple time-varying covariates, both with and without 
censoring at discharge from the PICU, are shown in Table 3.1. 
In order to further explore the relationship of platelet count with clinically 
significant bleeding, and to attempt to identify a threshold of platelet count that 
might be of clinical use, the Cox proportional hazard model was reconstructed 
using a discretized variable based on platelet count: the variable had a value of 1 
if the platelet count was greater than or equal to a threshold value, and 0 if the 
platelet count was less than the threshold value. Figure 3.3 shows the HRs for 
clinically significant bleeding at various threshold values for platelet count based 
on Cox proportional hazard models with only platelet count as a time-varying 
covariate. Figure 3.4 shows the results of this analysis when repeated with Cox 
proportional hazard models that included INR, PTT, and fibrinogen as well as 
platelet count as time varying-covariates. 
Clinical variables were selected, from among those identified as potential 
risk markers in the retrospective study, for inclusion in models examining the 
association of platelet count with clinically significant bleeding. (Because there 
was no suggestion in univariate models of any association between INR, PTT, or 
fibrinogen concentration with clinically significant bleeding, these variables were 
not re-examined in expanded multivariate models.) A causative association 
between thrombocytopenia and clinically significant bleeding is biologically 
plausible. For this reason, a multivariate model was constructed specifically to 
explore the ability of platelet count to explain clinically significant bleeding , rather 
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Figure 3.3: Hazard Ratios for Clinically Significant Bleeding for Patients 
with Platelet Counts Above or Below Various Thresholds 
Hazard ratios (on the vertical axis) for clinically significant bleeding are for 
patients whose platelet count is less than the threshold value given by the 
position on the horizontal axis, compared to patients whose platelet count is 
greater than that threshold value. 
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Figure 3.4: Hazard Ratios for Clinically Significant Bleeding for Patients 
with Platelet Counts Above or Below Various Thresholds, with Adjustment 
for INR, PTT, and Fibrinogen Concentration 
Hazard ratios (on the vertical axis) for cl inical ly significant bleeding are for 
patients whose platelet count is less than the threshold value given by the 
position on the horizontal axis, compared to patients whose platelet count is 
greater than that threshold value. 
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than to try to construct the best predictive model(23). 
To th is end, clinical risk markers were identified that were potential 
confounders for platelet count: variables that might have both an association with 
platelet count and an association with clinically significant bleeding independent 
of the relationship with platelet count. Considering the clinical risk markers 
examined in the retrospective study, potential confounders of platelet count were: 
admission for cardiovascular surgery (n = 26 patients), which is associated with 
thrombocytopenia and which may increase bleeding risk through derangements 
of other components of hemostasis as well ; admission for infection (n = 48), 
because infections can cause thrombocytopenia and may also cause 
consumptive coagulopathies that could increase bleeding risk; use of antibiotics 
(n = 81 ), which are among the medications most commonly implicated in 
medication-associated thrombocytopenia(24) and can also decrease coagulation 
factor levels by inducing abnormalities of vitamin K metabolism; and use of 
unfractionated heparin (UFH) (n = 31 ), which directly antagonizes some 
coagulation factors and can decrease platelet count through an immunologic 
mechanism (heparin-induced thrombocytopenia [HIT]) that can occur in pediatric 
patients(25). These were all identified as risk markers in the retrospective study, 
with the exception of admission for infection. (There was no effect of admission 
diagnosis except for those patients admitted for cardiac surgery, and specific 
medical diagnoses, such as infection, were not considered separately.) 
However, this variable was considered a potentially important confounder. 
Clinical variables that were identified as risk markers in the retrospective 
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study but were not included in the analysis here include mechanical venti lation 
(there is no direct mechanism by which this might affect platelet count) and use of 
antacid medications (which are likely less common causes of thrombocytopenia 
than are antibiotics(24 )). Low molecular weight heparin (LMWH) is a less 
common cause of HIT(25) than UFH and was used in only 7 patients, so LMWH 
heparin was not included . Admission for trauma could possibly be a confounder, 
but only 5 patients had this admission diagnosis, and so this was not included. 
The existence of unknown confounding variables cannot be excluded . 
Since there were only 31 patients who experienced clinically significant 
bleeding, we sought to reduce the number of variables analyzed by examining 
correlations between variables using Fisher's exact test. Admission for cardiac 
surgery was strongly correlated with both UFH use (95% Cl for OR= [42, 1131], 
p << 0.001 ) and antibiotic use (95% Cl for OR = [4.4, 57], p << 0.001 ) at any 
time during the period of data collection. Admission for infection was also 
correlated with antibiotic use (95% Cl for OR= [1.3, 5.7] , p = 0.002). Given these 
associations, the time-invariant variables admission for card iac surgery and 
admission for infection were selected for inclusion in a multivariate model. 
In a Cox proportional hazards model including platelet count as a time-
varying covariate and admission for cardiac surgery and admission for infection 
as time-invariant covariates, the association between platelet count and clinically 
significant bleeding was of borderline statistical significance (HR = 0.72 per 
increase in platelet count of 100 x 109 I L, 95% Cl = [0.516, 1], p = 0.0497); 
admission for card iac surgery had a significant association (HR = 2.68, 95% Cl = 
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[1.14, 6.29], p = 0.023) and admission for infection did not (HR = 0.80, 95% Cl = 
[0.292, 2.21], p = 0.67) 
3.4 Discussion 
This is the first prospective study of clinically significant bleeding in the 
PICU that attempted to capture clinically significant bleeding at all possible 
anatomic sites (except excessive chest tube bleeding in cardiac surgery 
patients). Using this approach, we found that the incidence of clinically significant 
bleeding in the first 72 hours of PICU admission was 13%. This is higher than 
the incidence in our retrospective study (Chapter 2), and is also higher than any 
incidence reported in other published literature(5,6). 
Given the difficulty in reliably identifying cases of clinically significant 
bleeding retrospectively, it is likely that prospective study results in a higher 
incidence because of improved case-finding . It appears that case-finding can be 
improved through prospective study, so that any further investigations of cl inically 
significant bleeding in the PICU should be conducted prospectively. The results 
of studies conducted retrospectively should be interpreted with caution. 
Of particular interest is the comparison between the Kaplan-Meier curves 
in Figures 2.1 and 3.2. The former demonstrates a "shoulder" just after the time 
of admission, during which time few clinically significant bleeding events were 
observed; this "shoulder" is absent in the latter curve. While this difference may 
simply be due to chance, it is also possible that it demonstrates a difficulty in 
reliably documenting bleeding during the typically busy time around a patient's 
admission to the PICU , further supporting the notion that bleeding in PICU 
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patients should be studied prospectively. 
In order to reliably capture bleeding events near the time of admission, one 
approach might be to institute formalized bleeding assessment as part of the 
routine of admission . Tools adapted from those of Arnold et al .(20) or the 
Neonatal Bleeding Assessment Tool (NeoBAT)(26) could easily be incorporated 
into routine admission documentation. This may improve the detection of 
clinically significant bleeding events near the time of admission, although this 
assertion would have to be proven systematically. 
The incidence of clinically significant bleeding we report here is 
considerably higher than other reports, which only consider bleeding at specific 
anatomic sites(5-7). Our results demonstrate that this limited approach 
underestimates the scope of bleeding as a clinical problem in PICU patients. 
Ten patients (32% of the patients with clinically significant bleeding, 4% of 
all included patients) had more than one episode of clinically significant bleeding . 
Analysis of the characteristics of these repeat bleeders has been deferred . 
The timing of clinically significant bleeding in the PICU is described in 
Figure 3.2. Clinically significant bleeding occurs most often early during an 
admission to the PICU , with the Kaplan-Meier curve showing evidence of 
"flattening" as time goes on . As in the pilot retrospective study, it is difficult to 
comment on bleeding risk for patients admitted to the PICU longer than 48 hours, 
because of small patient numbers and wide confidence intervals on the Kaplan-
Meier curve. 
The most important part of our analysis involves commonly-used 
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laboratory tests of hemostasis such as platelet count, INR, PTT, and fibrinogen 
concentration. Of these, only platelet count had a statistically significant 
association with clinically significant bleeding . This association persisted, with a 
p-value bordering on 0.05, after inclusion of potentially confounding clinical 
variables (admission for cardiac surgery and admission for infection) in the 
model. Unfortunately, the number of observed episodes of clinically significant 
bleeding limited the number of variables that could be included in the model. 
Cardiac surgery has a strong association with cl inically significant bleeding (9 
patients out of 26 admitted after cardiac surgery had episodes of clinically 
significant bleeding), and likely confounds the association between platelet count 
and clinically significant bleeding to some extent. However, the results obtained 
in this study suggest that reductions in platelet count do influence bleeding risk 
independently of this factor. 
One possible explanation for the observed association with platelet count 
and lack of association with INR and PTT is that perhaps platelet count is the 
only one of these laboratory parameters that actually is associated with clinically 
significant bleeding. Platelets have a number of functions in hemostasis, 
including adhesion and aggregation during formation of the initial platelet plug, as 
well as providing the surface on which the coagulation cascade is activated, 
ultimately forming of a cross-linked fibrin mesh(27). Thrombocytopenia might 
then be expected to result in significant impairment of hemostasis. An effect of 
thrombocytopenia on fibrin formation would be undetected by the PTT and INR, 
as these tests are performed with plasma rather than whole blood, with acellu lar 
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substitutes for the phospholipid membrane of platelets. 
PTT and INR, on the other hand, measure only the function of coagulation 
factors. Furthermore, they are not equally sensitive to all coagulation factors . 
The INR, for example is very sensitive to factor VII , which makes it a useful test 
for monitoring the effects of coumarin vitamin K antagonists(28). These tests 
were not designed as tests of global hemostatic potential , and there are no data 
to support their use in this manner in general populations of pediatric patients. 
Fibrinogen, while an important part of coagulation, is only a single factor, and so 
is likewise not a test of global hemostatic potential. Furthermore, congenital 
fibrinogen deficiency has an extremely variable clinical phenotype, including 
some patients with minimal bleeding symptoms(29), suggesting that fibrinogen 
concentration alone does not predict bleeding. 
Another possible explanation of our failure to observe an association 
between INR, PTT, or fibrinogen concentration and clinically significant bleeding 
is that these tests were performed less often than was measurement of the 
platelet count: platelet count was measured an average of 1.23 times per 24 
eligible patient-hours, compared to 0.58 times for INR and PTT and 0.57 times for 
fibrinogen concentration. A larger study, a study in which these latter 
measurements were made more frequently, or a study in which these 
measurements were made in a systematic rather than an ad hoc manner might 
detect an effect that was not seen here. 
We explored the association of different threshold values for platelet count 
with clinically significant bleeding. Although estimated hazard ratios greater than 
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1 were seen for all platelet count thresholds, these were only statistically 
significant at lower thresholds (less than 240 x 109 I L). Even at some lower 
thresholds, wide confidence intervals prevented estimated hazard ratios from 
being considered statistically significant. 
Estimated hazard ratios do appear to increase at thresholds below 100 x 
109 I L. However an increase in hazard ratios for lower thresholds of platelet 
count was not seen in models incorporating INR, PTT, and fibrinogen 
concentration were included as additional time-varying covariates. Although 
these tests lacked predictive ability on their own, it is conceivable that coagulation 
factor deficiencies identified by these tests might have predictive value in the 
setting of thrombocytopenia. A larger study that included more patients with 
significant thrombocytopenia would be needed to investigate this further. 
Our retrospective study identified a threshold for platelet count (less than 
100 x 109 I L) that was associated with clinically significant bleeding. This same 
threshold was not identified in this prospective study. Reasons for this may 
include differences in study design (eg. duration of data collection or the number 
of measurements of platelet count that were included in the data set), study data 
(eg . a higher incidence of clinically significant bleeding was seen in the 
prospective study), or analytic technique (logistic regression vs. Cox proportional 
hazards models). It may be the case that, despite the clinical util ity of cutoff 
values, there does not exist a cutoff value for platelet count that clearly 
discriminates between patients with high and low bleeding risks. In this case, the 
identification of a cutoff value in the retrospective study may simply have been an 
55 
artifact of an inherently limited data collection. 
Ultimately our work would be of most interest if it could motivate change in 
the management of PICU patients who were at risk of clinically significant 
bleeding. Based on our results, correction of thrombocytopenia through platelet 
transfusion might seem a sensible strategy. However, the correct circumstances 
under which to do this are not clear. The hazard ratios shown in Figure 3.3 
suggest that a platelet count below 60 x 1 09 I L might be appropriate, but the 
exploratory analysis used to produce this figure should not be considered 
conclusive. Furthermore, it should not be assumed that, because 
thrombocytopenia is a risk marker for clinically significant bleeding, correction of 
thrombocytopenia would ameliorate bleeding risk. An experimental clinical study 
would be the only way to prove the utility of platelet transfusion for 
thrombocytopenic patients in the PICU. 
3.5 Conclusions 
Prospective detection of clinically significant bleeding in pediatric intensive 
care unit patients demonstrates that clinically significant bleeding is more 
common than previously reported. Clinically significant bleeding is a complication 
most often seen early in an admission to the PICU. Platelet count is associated 
with clinically significant bleeding , but INR, PTT, and fibrinogen concentration are 
not. More extreme thrombocytopenia may be associated with greater hazard of 
clinically significant bleeding. Our results provide sufficient rationale to justify an 
experimental evaluation of platelet transfusion to prevent bleeding complications 
in selected PICU patients with severe thrombocytopenia. 
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Chapter 4: Summary and Conclusions 
4.1 Incidence of Clinically Significant Bleeding in the PICU 
Our results, from both the retrospective and prospective studies, 
demonstrate that clin ically significant bleeding is more common among PICU 
patients than had been reported by previous studies that considered only 
bleeding from a specific site such as the gastrointestinal tract. 
Furthermore, we observed a higher incidence of clinically significant 
bleeding in the prospective study than in the retrospective study. This 
demonstrates that significant bleeding events are not reliably captured by medical 
records alone; this may be particularly true early in an admission to the PICU . In 
addition , the poor agreement between chart abstractors in identifying bleeding 
events in the retrospective study shows that events, even when documented in 
the medical record , may be difficult to recover retrospectively. Because of this , 
prospective observation should be required in any further studies of bleeding in 
PICU patients. 
In both the retrospective and prospective studies, we did not follow 
patients after discharge from the PICU, and cannot comment on the incidence of 
clinically significant bleeding post-discharge. It is likely that patients would have 
decreased bleeding risk after discharge, for a number of reasons: more advanced 
wound healing for surgical patients, less exposure to medications that might alter 
hemostasis, being subject to fewer invasive procedures, and improvement of 
conditions that cause thrombocytopenia, consumptive coagulopathy, or other 
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acquired causes of impaired hemostasis. However, there may be a risk of post-
discharge bleeding for some patients, which may be severe enough to require re-
admission to the PICU in some cases. The characteristics of such patients would 
have to be determined in a separate prospective study. 
In our prospective study, we did record multiple bleeding events for 10 
patients (32% of patients who had clinically significant bleeding events, and 4% 
of all patients). Since data collection in the retrospective study stopped with a 
clinically significant bleeding event, we have no estimate of the incidence of 
recurrent events from this study; however, it is to be expected that prospective 
data collection would provide a more accurate estimate of the incidence of this 
phenomenon. Determination of the characteristics of this group of repeat 
bleeders has been deferred . 
4.2 Timing of Clinically Significant Bleeding in the PICU 
Our pilot retrospective study is the first systematic examination of the 
timing of clinically significant bleeding among PICU patients. We found that more 
than 80% of episodes of clinically significant bleeding occurred within 48 hours of 
admission . Owing to small numbers of patients whose admissions lasted longer 
than 48 hours, it was not possible to conclude whether bleeding risk declines 
significantly over time for patients with prolonged admissions. 
In spite of this, it is reasonable to suggest that patients be closely 
observed for the occurrence of bleeding early during their admissions. Since our 
prospective study only followed patients to a maximum of 72 hours after 
admission to the PICU , it contributes no information to a discussion of bleeding 
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risk for patients with prolonged PICU admissions. 
4.3 Clinical Risk Markers for Clinically Significant Bleeding 
Our retrospective study identified a number of clinical risk markers for 
clinically significant bleeding, including some that '?~e theoretically modifiable 
(thrombocytopenia, mechanical ventilation , antibiotic and antacid medications, 
multiple procedures) and some that are not (cardiac surgery, for example). 
Treatment-related risk markers, however, might not be modifiable in practice. For 
example, a patient might require mechanical ventilation in spite of a perceived 
bleeding risk associated with this therapy. 
Because only a small number of clinically significant bleeding events were 
observed in the retrospective study, it was not possible to simultaneously 
evaluate many clinical risk markers in a multivariate logistic regression model. 
Consequently, we cannot comment on whether these are all independent risk 
markers. It may be the case that some of these variables are correlated with one 
another and that their associations with bleeding risk are not, therefore, 
independent of one another. 
The prospective study was designed specifically to examine the 
association between laboratory tests of hemostasis and clinically significant 
bleeding. However, analysis of clinical variables was performed in a multivariate 
model including platelet count: admission for cardiac surgery was significantly 
associated with clinically significant bleeding , and admission for infection was not. 
However, the number of clinical variables analyzed was limited by the number of 
observed episodes of clinically significant bleeding. Our prospective study was 
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deigned primarily to examine laboratory variables, and it is possible that 
important clinical variables were not examined. 
An important use for observed clinical risk markers is to identify patients 
who are at increased risk so that they can be monitored closely for bleeding 
complications. Our work helps to identify such patients. However, appropriate 
interventions to reduce bleeding risk in patients with these risk markers remain to 
be identified . 
4.4 Laboratory Risk Markers for Clinically Significant Bleeding 
In both the retrospective and prospective studies, platelet count was seen 
to have an association with clinically significant bleeding. INR, PTT, and 
fibrinogen concentration did not. In the prospective study, this was in spite of a 
more sophisticated and thorough analysis that included measurements at 
multiple time points (when available) and imputed corrections following 
transfusion of hemostatically active blood products. 
An exploratory analysis of platelet counts in the prospective study 
identified 60 x 109 I Las a threshold that might be of interest: this is the threshold 
below which the hazard ratio for clinically significant bleeding appeared to 
increase. 
The possible reasons for the lack of association of other tests with 
clinically significant bleeding were discussed in Chapter 3. In the end, either 
these tests do not have predictive ability at all or these tests are not sufficiently 
strong risk markers to have been identified by our studies. In either case, INR, 
PTT, and fibrinogen concentration should not be considered to be strong 
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predictors of hemorrhagic risk. 
The use of laboratory tests that have not been demonstrated to possess 
predictive value carries potential risks. Abnormal values of these tests may 
prompt interventions that, while they may correct the abnormal test result, might 
not reduce bleeding risk. These interventions involve exposure to blood 
products, which can cause acute transfusion reactions(30) and transfusion-
associated acute lung injury(31 ). In the face of these known risks, it is 
questionable to apply interventions of unknown efficacy. 
4.5 Limitations 
Our pilot study had limitations typical of retrospective studies; these 
limitations have already been discussed at length in Chapter 2. The most 
significant of these limitations was the difficulty in identifying cases of clinically 
significant bleeding . Comparison of our two studies suggests that bleeding 
episodes that occur very shortly after admission to the PICU might be particularly 
difficult to identify from medical records alone. The clear lesson is that clinically 
significant bleeding cannot be reliably identified solely from medical records . 
Prospective identification of clinically significant bleeding, using a broadly-
inclusive definition similar to the one used in our studies, does appear to be 
reliable(20). We do not, therefore, expect that the results of our prospective 
study will have been biased by the omission of a particular subset of bleeding 
episodes. However, the reliability of our definition of clinically significant bleeding 
in prospective data collection was, for practical reasons, not assessed and should 
be confirmed in a subsequent study. 
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Criticism of our studies may be directed at our definition of clinically 
significant bleeding. The likely forms of these criticisms will be either that there is 
subjectivity involved in our definition or that our definition does not differentiate 
between bleeding events of differing severity. Both of these points are true, but 
these are not, in fact, significant limitations of our definition of clinically significant 
bleeding. 
There is subjective assessment involved in our definition of clinically 
significant bleeding events. This subjectivity takes two forms: the attribution of 
signs, symptoms, or interventions to bleeding; and the decision to perform 
interventions in response to bleeding . But it is not clear that more objective 
criteria for defining significant bleeding would be more useful. 
The most objective possible criterion , for example, would be the volume of 
blood loss. In post-operative pediatric cardiac surgery patients, it is possible to 
directly measure the volume of blood loss through chest tubes, and this has been 
used to classify some bleeding as excessive(1 ,2). However, the volume of chest 
tube bleeding that is considered excessive is itself subjectively defined, which is 
to say defined according to the subjective judgement of other investigators. 
Furthermore, such precise quantitative measurements of blood loss are not 
possible in most other patients. Even more complexity is added when one 
considers bleeding in different sites. A volume of bleeding that might be of minor 
concern in one site, such as the gastrointestinal tract, may be catastrophic in 
another, such as the intracranial space. These points demonstrate that the most 
objective possible method for gauging the severity of bleeding , measurement of 
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the volume of bleeding, is of little practical use. 
There are no evidence-based systems of classification of bleeding 
according to whether specific intervention is required . (The lack of such 
algorithms was one of the motivations for our studies.) In this circumstance, 
relying on the judgement of treating physicians to contribute to the identification 
bleeding that requires intervention is reasonable and not without precedent. 
Physician judgement has been successfully incorporated, for example, into 
clinical decision rules for identifying patients who require imaging to detect deep 
vein thromboses(32) and pulmonary embol i(33). 
It is also true that our definition does not differentiate between bleeding of 
different severities, as long as one or more criteria for clinically significant 
bleeding are met. There are available grading systems for bleeding, such as the 
World Health Organization (WHO) classification(34) and the Buchanan system 
for grading bleeding associated with immune thrombocytopenic purpura(35), but 
these systems are semi-quantitative and somewhat arbitrarily-defined . 
Furthermore, it has not been established that such classifications are of any 
practical use in guiding management or indicating prognosis. There is, therefore, 
no rationale for attempting to subdivide bleeding events according to severity. 
Both of the studies we performed were purely observational , and as a 
result cannot definitively establish causation between putative risk markers and 
clinically significant bleeding. We cannot, therefore, recommend any 
interventions to decrease bleeding risk, based on our studies. 
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4.6 Significance and Further Directions 
Our results provide the most complete and sophisticated description and 
analysis of clinically significant bleeding in the PICU to date. The pilot 
retrospective study identified clinical risk markers for cl inically significant 
bleeding , and demonstrated that most episodes of clinically significant bleeding 
occur early during admissions to the PICU. These observations suggest patient 
characteristics and time frames that should prompt vigilant monitoring for 
clinically significant bleeding. 
In terms of preventing clinically significant bleeding, comparative studies of 
carefully chosen interventions are required. Based on our data, the best 
candidate for such an intervention is platelet transfusion. Both our retrospective 
and prospective studies identified thrombocytopenia as a significant risk marker 
for clinically significant bleeding. Moreover, there is obvious conceptual rationale 
for attempting platelet transfusion in order to correct thrombocytopenia and 
possibly ameliorate bleeding risk. An appropriate patient population to study 
would have to be identified. In other words, a level of thrombocytopenia that 
might be expected to benefit from platelet transfusion - a transfusion threshold -
would need to be determined. 
Restricting attention to that minority of patients with a significant degree of 
thrombocytopenia would likely mean that a study of prophylactic platelet 
transfusion would have to be conducted across several centres, in order to 
accrue enough patients. Fortunately, in Canada platelet concentrates are a wel l-
standardized product. Furthermore, platelet counts are a reproducible test. A 
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multi-centre trial of prophylactic platelet transfusions, then, would seem to be 
feasible. 
This study would be most efficient if it employed a comprehensive 
definition of clinically significant bleeding , such as the one that we employed in 
our studies. By using a broadly-inclusive definition of clinically significant 
bleeding , we were able to demonstrate a higher incidence of clinically significant 
bleeding, particularly when this definition was applied prospectively, than any 
previous study. In the context of a randomized trial, this translates into more 
outcome events, potentially a larger absolute risk reduction with the proposed 
intervention, and ultimately a smaller intended sample size for the trial. 
Another important function of such a study would be to investigate the 
possible effect of abnormal values of INR, PTT, and fibrinogen concentration on 
bleeding risk in the setting of significant thrombocytopenia. Because a 
randomized trial of prophylactic platelet transfusions would require consent from 
patients or their substitute decision-makers, the study protocol could include 
systematic collection of these other laboratory parameters, to better examine 
their importance. 
This effort could produce data that would provide more rational use of 
laboratory investigations and blood products . Most importantly, improved patient 
care could result. 
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Pmient' Initials: l_l_l_l Patient Enrolment Number: ____ ,_ I 
DEVELOPI G A P RE DICTION TOOL fO R 
C LI NI CALLY SIG IF ICANT BLEEDI 'GIN THE PIC 
CASE R EPORT fOR.I\1 
I. DE;\'IOG RAPHICS 
1.1 Date of Birth: l_l_l l_l_l_l l_l_l_l_l 
D D I MMiv/ IY E AR 
1.2 Admission to PICU date/time: l_l_l l_l_l_l 12 I 0 I 0 I 9 I at 1_1_1:1_1_1 
DD I MM!'vi / YEAR HHMM 
I.3 Gender: l_l ivlale I_I Female 
1.4 Weight: LLL Ll kg 
1.5 Admission Diagnosis: --------------------
2. EXCLUSION C R1TER1A 
2. 1 Admitted to PICU for bleeding LIY•·' Ll no 
lf "yes", specify site ________ _ 
2.2 Previously diagnosed bleeding disorder Llyes Ll tro 
If "yes", specify __________ _ 
2.3 Weight < 5 kg 
2.4 ge < 2 months (60 days) or >= 18 years 
2.5 Prior inclusion during study period 
lf ·'yes", record Enrolment ;I ____ _ 
l_l Eligible -+ Complete C R f 
Llyes Ll tro 
L lyes L l no 
L lyes L l no 
l_l Excluded (if meers any exclusion criteria) -+ Do not collect other data 
page I of 4 
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Patient's Initials: __ l_l Patient Enrolment Number: I_ I __ 1_ 1_ 1 
3. CLI ' ICAL DATA 
3. 1 Vitals at admission 
Hean rate I beats I min 
Blood pressure I I mmHg 
Respiratory rate I breaths I min 
0 2 Sat 
I 
% 
on %02 L I min 
Temperature ___ oc 
I I oral I I rectal I I axillary I I bladder 
3.2 Nutrition: l_l NPO 
-
TPN 
-
tube feed, peci fy device: 
-
oral 
3.3 Respiratory support: l_l yes, specify type l_l no 
3.4 Antibiotics (started from 24 hours before admission to 6 hours after admission) 
Drug Dose Route Frequency Date I Time of I" Administration 
(specify units) I (specify units) DD / M .'4M / Y £ AR fl I I · MM 
I lu_u_u 12 10 10 19 1 lu_l:l_u 
I Ju_ u _u 2 10 10 9 lu_I: I_U 
1-uu_u 2 10 10 9 U_I:I_U 
3.5 Antacids (started f rom 24 hours before admission to 6 hours after admission) 
Drug Dose 1 Route Frequency Date I Time of I" Administration 
(specify units) (Sp CCify UntlS) D D I .H M .H IY £ A R Hfl .\1M 
__ u_u 2 10 10 9 1_,_: ,_ ,_1 
I II_UU_U 2 0 10 19 U_I:I_U 
3.6 Steroids (starred f rom 24 hours before admission to 6 hours ajier admission) 
Drug Dose J Route Frequency I Date I Time of I" Administration 
(specify units) (spcoify units) D D / .'4MM !Y£AR fl fl : Jl .H 
__ 1_1_1_1 2 0 10 9 ._ 1_ : 1_ ,_1 
1_1_11_1_1_1 2 10 10 9 U_':I_U 
page 2 of4 
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Patient 's Initials: l_l_l_ l Patient Enrolment Number: l_ l_l_l_l_l 
3. 7 Anticoagulants (.started ji-om ]4 hours bejOre admission to 6 hours ajier admission) 
Dmg Dose 
(spcc1fy units) 
Route Frequency 
(specify units} 
Date I T ime of I" Administration 
D D I .11 .~1 .11 IY E A R N N · M M 
1_ 1_1 1 ___ 112 010191 IU_I: I_U 
11_u _ ,_u 1210 o191 1-u' u_l 
3.8 Procoagulants (started f rom 24 hours before admission to 6 hours after admission) 
Dmg Dose 
I 
Route Frequency Date I Time of I" Administration 
(specify units) (specify unitS) D D I M M .11 IY E A R HI/ · M M 
I I_U _ ,_1_1 121010191 1-U:I_U 
j i_U 1_1_1_1 12 010191 1·_ ._ :1_1_1 
3.9 Blood Products (givenji-om 24 hours before admission to 6 hours ajier admission) 
Product I Dose Date I Time of Administration 
(specify un its} D D I M M.11 /YEA R HH · MM 
I I_U I_ I __ I 21 0 I 0191 1_1_1:1_1_1 
I_U U_U 121 o I o 191 U_I:U_I 
l_u u _u 121010191 1_1_1:1_1_1 
I I_U U _U 121010191 I_,_: I_U 
u_l l __ u 121010191 1 __ ':1_1_1 
3.10 Procedures (perjormedji·om 14 hours before admission to 6 hours ajier admission) 
Procedure Date I Time of Procedure 
D D I .11 M M IY E A R N H : Mlvf 
'--' u_u 121010191 l_ l_ : I_U 
_1_1 u_u 121010191 1_ 1_ : I_U 
U _I I_U_i' 121010 191 U _I:I_U 
l_u u_u 121010 19 U _ I:I_U 
U_IU_ U 12 1010 9 11_ 1_1: 1_1_1 
I '-'-' u_u 12101019 U _I:U_I 
I l_ u u_u 121010 19 1_ 1_ 1: 1_1_ 1 
jl_ u u _ u 12 1010 91 _l_t: l_l_l 
page 3 of4 
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J 
I 
I 
Patient's Initials: l_l_l_l Patient Enrolment Number: l_ l __ 1_ !_ 1 
4. LABORATORY DATA ( Values closest to date & time of admission) 
Test Result Date I Time o f Test 
D D I M M .11 IY £ A R fl II : .\1M 
Hemoglobin g i L 
l_ l_ IU_ U 210 10 19 1 U _ I: I_ U 
Pla telet 1_1 clotted X 109 IL 
Count 
1_1 periph 
PTT Ll art line s 
1_1 CVl.. l_ u u _ u 12 10 10 19 1 U _ I: I_ U 
Fibrinogen g i L 
IN R I 
ALT U I L 
U _ IU_U 2 o I o 19 1 I __ I: U_I 
AST U I L 
Creatinine ,umol I L 
I_U U _ U 12 0 10 19 I _ 1_1: 1_1_ 
Urea mmol I L 
pH I_I ABG 
pC02 I_I CBG mm Hg 1_1_11__1_1 12 0 10 19 _,_1: 1_1_ I 
HC0 3. I_I VBG mmol I L 
5. OUTCOME 
l_l Episode o f clinicall y significant bleeding--+ Complete CRF for bleeding episode 
1_1 Duration of PICU admission > 7 days 
1_ 1 Discharge from PICU on l_l_l l_l_l_l I 2 I 0 I 0 I 9 I at l_l_l:l_l_l 
D D ! Mlv!MI Y E AR H H t\llvf 
l_l Death on l_ l_ l l_ l_ l_ l I 2 I o I o I 9 I at 1_1_1:1_1_1 
DD ! tV!M lvf ! YEA R HH/vl /vl 
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Patient's Initials: 1_1_ 1_ 1 Patient Enrolment Number: l_ l_l_l_ l_ l 
DEVELOPING A PREDICTION T OOL FOR 
CU NICALL Y SI GNIFICANT BLEEDING IN T HE PICU 
CASE REPORT FORM - SI GNIFICANT BLEEDING EVENT 
I. BLEEDING EVENT 
1.1 Date and time of bleeding event: l_ l_ , l_ l_ l_ l I 21 0 I 0 19 I at 1_ ._ 1:1_ 1_ 1 
DD ! MMM I YEAR HHMM 
1.2 Detection of bleeding event (specifY site): 
l_ l Clinical observation:------------------------
1_1 Radiographic observation: ----------------------
1.3 T ype of bleeding event (indicate all that apply) : 
I. Blood loss or hematoma formation is thought to have caused any of the following: 
l_ l Death 
l_l Hypotension (PALS definition) 
l_l Decrease in hemoglobin concentration by at least 20 g I L from baseline 
2. Blood loss or hematoma fo m1ation caused signi ficant symptoms or impairment of function. 
1_ 1 Specify:------------------ ------
3. Blood loss or hematoma formation resulted in any of the following interventions: 
1_ 1 Cardiopulmonary resuscitation 
l_l Surgical management of b lood loss (specify below) 
l_ l Major revision or re in forcement of a surgical dressing (specify below) 
l_l Procedural or operative investigation o f blood loss (specify below) 
1_1 Usc of volume expanders in volumes > 20 mL I kg (specify below) 
1_ 1 Transfusion of PRBC 
l_l Use of medication or blood products to control bleeding (specify below) 
1_ 1 Cessation of anticoagulation medication (specify below) 
l_l Delay or avoidance of an essent ia l or urgent procedure or intervention (specify below) 
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Patient's Initials: l_l_ '_ Patient Enro lment Number: ._ ._ l_ l_ l_ l 
2. MANAGEMENT (in rhe 6 hours following clinically signijica/71 bleeding evenr) 
2. 1 Volume Expanders (excluding PRBCs - lisr under Blood Producrs) 
Volume Expander Dose I Volume Date I Time of Administration 
(specifY u11i1s) D D I .'4 M .'4 IY £ A R HI/ M .'4 
I I_ UI ___ I 1 010 91 , 1_ 1_ 1: --
I I_I_I U _U 2 0 0 191 11_1_1: !_ 1_ 1 
2.2 Blood Products 
i Blood Product Dose Date I Time of Administration (specify '""rs) D D I .'4 .'4 M y £ A R HH .'4 .H 
I I_U __ _ I 110 0 9 1 __ :1_1_1 
I 1_1_11_ ,_ ,_ 1 2 0 019 1 _ 1_ !: 1_ 1_ 1 
1_1_1 ___ 11 2 0 0191 _ 1_: 1_1_1 
2.3 Medications (sropped or srarred - dose/roure!frequency a11d dare/rime if srarred) 
Medication Dose 
1 
Route 
1 
Freq Date I Time of I" Administration 
(units) (unirs) 
or Stopped D D I MMMIY £ A R Il l/ MM 
I I 1_1_1_, __ 1 2 0 019 1 I_I_ I: I_ U 
l_l sropped 
I I l_l_ll_ __ ll 2 0 019 1 I_I_I:I_U 
I I_J sropped 
I I I 1_ 1_11 __ 1_ 1 2 o I o 19 1 U_I: I_U 
I_J sropped 
2.4 Procedures & Investigations (delayed or pe~formed- dare/rime if performed) 
I Procedure or Investigation Delayed or Performed Date I Time of Procedure or Investi gation D D I M .'4 M IY £ A R H H ,'4 ,';/ 
I l_ l delayed I_ I performed --'-'- '-' 21010 9 1_1_1: __ 
I l_ l delayed l_l performed 1 __ 1 _ 1_1_ 121010 9 1_1_1: 1 __ 1 
l_l delayed l_ l performed _ l_ll_l_l_ 21010 9 1_1_1: 1_!_1 
2.5 Control of Bleeding: L l yes l_l no l_l uncertain 
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Appendix 2: Instructions for Case Report Forms for Retrospective Study 
DEVELOPING A PREDICTION TOOL FOR 
CLINICALLY SIGNIFICANT BLEEDING IN THE Pl CU 
CASE REPORT FORM- INSTRUCTIONS 
General Instructions 
At the top of each page, enter the Patient's Initials (first, last), and the Patient 
Enrolment umber 
Enter dates in the fonnat DD I MMM I YYYY (i.e. October 22, 1998 is 
22 I OCT I 1998) 
Enter times according to the 24 hour clock in the format HH:MM (i.e. 4 pm is entered 
16:00) 
If data is not applicable, not known, illegible, or incorrect, enter I A. 
To correct an entry, draw a line through the incorrect response, write and circle your 
initials, record the date of the correction, and enter the valid infonnation. See example 
below: 
Blood Pressure: 120 I +6- 93 8 12/Dec/02 
1. DEMOGRAPHICS 
1.3 Take date and time of PICU admission from nursing admission note. (If time of 
admission is not available there, may take from other sources, such as PICU flow sheet or 
physician order sheet.) 
1.5 Use weight at time of admission to the PICU, taken from nursing admission note. (If 
weight is not recorded on nursing admission note, may take from other ources, such as 
ER documentation, physician order sheet, or PICU flow sheet.) 
1.6 Admission diagnosis is to be determined from documentation at admission (nursing 
note, physician note). 
2. EXCLUSION CRITERIA 
Determination of whether a patient meets an exclusion criterion is based only on 
information available at time of admission. 
A patient may meet more than one exclusion criterion. If a patient meets any of the 
exclusion criteria, mark as "Excluded", and collect no further data. 
2.1 A patient meets this criterion if admitted to the PICU specifically for control or 
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monitoring of bleeding. Intra-operative bleeding does not meet this criterion, unless it is 
not controlled at the time of admission to PICU. lf a patient is admitted to the PICU 
because of bleeding, specify the site. 
2.2 lf a patient has a previously diagnosed bleeding disorder, specify the disorder. 
2.5 If a patient has a prior inclusion during the study period, record the enrolment number 
of that prior inclusion. 
3. CLINICAL DATA 
3.1 Use vitals as recorded on nursing admission note. If data are not recorded on nursing 
admission note, take flrst recorded value from PICU flow sheet. 
If patient is on room air, record as 21 % 02. 
Record site of temperature measurement. 
3.2 Record patient's ource of nutrition at time of admission to PlCU. If patient is tube 
fed, specify device (ex. G tube, G-tube). 
3.3 If a patient is receiving respiratory support at time of admission to P JCU, record type 
(ex. CPAP, BiPAP, I + V). If intubated and ventilated, specify type of ventilation (ex. 
Conventional, HFOV, HFN). Supplemental oxygen alone, whether given by nasal 
prongs or facemask, should not be recorded as respiratory support and should be recorded 
under vitals (3.1). 
3.4 - 3.9 Record only medications or blood products given during the period from 24 
before admission to PICU to 6 hours after admission to PICU. Record date and time of 
first administration during this period. Record medications taken at home that are likely 
to have been taken in the 24 hours prior to admission to PICU, even if administration is 
not documented, and record date I time as "home med". Do not record medications or 
blood products given after an episode of clinically significant bleeding. 
Record generic drug name, dose including units, route of administration, and frequency 
for al l drugs. Record "x 1" for a one-time dose of a drug, including date and time of the 
dose. For a drug given as a continuous infusion, record any bolus dose as a one-time 
dose; record rate of infusion, record frequency as "infusion", and record date and time of 
beginning of the infusion. 
3.4 Do not include topical or inhaled antibiotic drugs. 
3.5 Including ranitidine, pantoprazole, omeprazole, lansoprazole, aluminum hydroxide. 
3.6 Include corticosteroids only. Do not include topical or inhaled steroid drugs. 
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3.7 Including warfarin, unfractionated heparin (UFH) given as an infusion or in bolus 
doses greater than 10 units I kg, low molecular weight heparin (LMWH, Enoxaparin, 
Dalteparin, Tinzaparin), aspirin (ASA), ibuprofen, ketorolac, indomethacin, celecoxib, 
tissue plasminogen-activator (tP A, Alteplase ). 
3.8 Including vitamin K, protamine, tranexamic acid (Cyclokapron), desmopressin 
(DDA VP, Octostim). Factor concentrates should be recorded under "Blood Products" 
(3.9). 
3.9 Include all blood products, including packed red blood cells (PRBCs), platelets, 
albumin, immunoglobulin concentrates, factor concentrates (including Octaplex or PCC) 
and recombinant products. Include blood products used for cardio-pulmonary bypass. 
3.10 Include all procedures, even if not successful. Include insertion of central venous 
lines and arterial lines, but not peripheral intravenous lines. Include surgery, even if this 
has been recorded under "Admission Diagnosis" (1.5) . Do not include minor suturing, 
arterial line removal, central venous line removal, extubation, Foley catheter removal, or 
other minor procedures. 
4. LABORATORY DATA 
Record only data obtained during the period from 24 before admission to PICU to 6 hours 
after admission to PICU. In the case of repeated testing, use results obtained closest to 
time of admission. Record date and time of test. 
For plate let count, if specimen is reported as "clotted", record result, indicate as "clotted". 
For PTT, record source of sample. 
For blood gasses, indicate if arterial (ABG), capillary (CBG), or venous (VBG). Use test 
taken closest to the time of admission. In the case that two different blood gases are taken 
at the same time, use ABG or, if ABG is not available, use CBG. 
5. OUTCOME 
Record one and only one outcome for each patient. 
If a patient has an episode of clinically significant bleeding, complete Case Report Form 
for that episode. 
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DEVELOPING A PREDICTION TOOL FOR 
CLINICALLY SIGNIFICANT BLEEDING IN THE PICU 
CASE REPORT FORM- SIGNIFICANT BLEEDING EVENT -INSTRUCTIONS 
General Instructions 
At the top of each page, enter the Patient's Initials (first, last), and the Patient 
Enrolment Number 
Enter dates in the format DD I MMM I YYYY (i.e. October 22, 1998 is 
22 I OCT I 1998) 
Enter times according to the 24 hour clock in the fom1at HH:MM (i.e. 4 pm is entered 
16:00) 
If data is not applicable, not known, illegible, or incorrect, enter Nl A. 
To correct an entry, draw a line through the incorrect response, write and circle your 
initials, record the date of the correction, and enter the valid information. See example 
below: 
Blood Pressure: 120 I "14- 93 @ 12/Dec/02 
1.1 Record date and time of bleeding event. If time of event is not clearly documented, 
record time of documentation. 
1.2 Record mode of detection of bleeding event (clinical or radiographic) and anatomic 
site of bleeding. If bleeding event is detected radiographically, record modality (ex. 
CT, MRI, US, . . . ). 
1.3 Record all criteria met by bleeding event (more than one may apply) . 
In order for a criterion to be met, it must be documented that the observed blood loss 
or hematoma formation is thought to have caused the observed effect on the patient 
or to have resulted in an intervention. 
1. Hypotension is defined according to Pediatric Advanced Life Support criteria: 
- systolic BP < 70 mm Hg for patients less than 1 year of age 
-systolic BP < 70 + 2 x (age in years) mm Hg for patients between 1 and 10 years 
- systolic BP < 90 mmHg for patients > 10 years of age 
In order to meet the criteria for decreased haemoglobin, haemoglobin 
concentration must be decreased by at least 20 g I L from the haemoglobin 
recorded in Section 4 of the patient's Case Report Form. 
2. Symptoms or impairment of function may include, but are not limited to: 
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- signs or symptoms of respiratory distress from hemothorax 
- signs or symptoms of cardiovascular dysfunction from hemothorax or 
hemomediastinum 
- signs or symptoms of spinal cord compression from paraspinal hemorrhage 
- signs or symptoms of neurologic dysfunction from intracranial hemorrhage 
- loss of visual function due to retinal or intraoccular hemorrhage 
- pain from hemarthrosis or hematoma formation resulting in loss of function or 
requiring treatment. 
3. Record interventions if they have occurred in response to bleeding. 
Include revision of central line dressings, arterial line dressings, or surgical 
dressings if the revision was due to bleeding. 
Volume expanders include: albumin 5%, pentastarch, 0.9% normal saline (with or 
without dextrose or other additives), Ringer's lactate. Use ofPRBCs is recorded 
elsewhere. 
Include use of medications that do not directly affect hemostasis, if the intent of 
giving the medication is to control bleeding. (ex. H2-blocker or PPI for 
gastrointestinal bleeding, inhaled or topical epinephrine for epistaxis.) 
2 Record management of bleeding if performed or begun within 6 hours of the bleeding 
event. 
2.1 Record volume expander used, dose used, and date/time of administration. Albumin 
5% should be recorded here. PRBCs should be recorded under Blood Products (2.2). 
2.2 Record any blood product used to replace lost blood (PRBCs) or to control bleeding 
(platelets, cryoprecipitate, FFP, PCC, human-derived or recombinant clotting factor 
concentrates) . 
2.3 Record any medications started or stopped to control bleeding. Record date I time of 
first administration or date I time of stopping. 
2.4 Record procedures or investigations performed to control bleeding or to investigate 
bleeding. Record planned procedures that were delayed because of bleeding. 
2.5 In order to record "yes", it must be documented that bleeding was stopped or 
satisfactorily improved, or that the bleeding was no longer evident (ex. for upper GI 
bleeding, documentation that an NG aspirate was no longer bloody). Similarly, 
documentation must clearly indicate that bleeding has not been adequately controlled 
in order to record "no". Otherwise, record "uncertain". 
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Appendix 3: Case Report Forms for Prospective Study 
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Patient Enrolment Number: l_l_l_l_l Patient's Initials: _ l_ l_ , 
DEVELOPING A PREDICTION TOOL FOR 
CLINICA.LL Y SIGNIFICANT BLEEDING IN TRE PICU 
CASE REPORT FORM 
1. DEMOGRAPHICS 
1.1 Date o f Birth : u _u _u_u 
MM'v1 1 YYYY 
1.2 Admission to PICU date/time: l_ l_ l l_ l_ l_ 111 0 I I I 0 I at 1_ 1_ 1:1 __ I 
(= T,dm") D D I M yl M I Y Y Y Y H H M M 
1.3 Gender: 1_ 1 Male ( 0) l_lfemale ( I ) 
1.4 Weight: LLLI-Li kg 
1.5 Admission Diagnosis : - ------- -------------
l_l Trauma ( I ) 
l_l Post-Op: General ( 2 ) 
l__j Post-Op: CVT ( 3 ) 
l_l Post-Op: Neuro ( 4 ) 
l_ l Post-Op: Onho ( 5 ) 
l_l Post-Op: Head & Neck ( 6 ) 
l_ l Post-Op: Other ( 7 ) 
l_l Medica l: Respiratory ( 8 ) 
I_ Medical: Respiratory Infection ( 9 ) 
1 Medical: Other Infection ( 10 ) 
1=1 Medical: Other ( II ) 
1.6 Surgical Patients Only - Estimated Blood Loss: l_ l_ l_l_l_l mL 
2. EXCLUSION CRlTERJ A 
2.1 Admitted to PICU for bleeding 
2.2 Previously diagnosed bleeding disorder 
2.3 Weight < 3 kg 
2.4 Age < 2 months (60 days) or >= 18 years 
2.5 Prior inclusion during study period 
2.6 Eligibili ty 
l_l Eligible ---> Complete CRF 
I_ . no I_ ' yes~ specify site: ______ _ 
1_1 no l__j yes - specify: ________ _ 
l_l no I_ : yes 
l_ l no 1_1 yes 
1_1 no U yes- Enrolment# l_ l_l_ l_l 
l_l Excluded (if meets any exclusion criteria)~ Do not collect other data 
page I of I 0 
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Patient Enrolment Number: _ l_l_!_, Patient's Initials: _l_l_ 
3. DAY 0: Start at T adm;,- 24 hours 
End at Tadm;, 
= _ _ ll_ l_l_ 12 0 
= _ _ ll_l_ l_ 12 0 
0 0 MMM 
0 at __ l:l_ l_ 
0 ar __ l:l_ l_ 
H H MM 
3.1 Vital Signs: 
Minimum Maximum 
HR (bco1s / min) 
Systolic BP (mmHg) 
RR (brc:uhs I min) 
O, Sat (%) 
Temp (0 C) 
I PO (Ill PR !c) I IAX !ll l BL !~l PO ill PR!2l l AXIl) I I BL 4) 
3.2 Supplementa l 0 ,: l_l no ( 0) Ll yes ( I ) --> __ % Fi02 or __ L I min 
3.3 Intubated: L1 no ( 0 ) L1 yes ( I ) 
Resp. Suppon: Ll conventional ( I ) 
1_1 ffFO VIHFJV ( 4 ) 
Ll CPAP ( 2 ) Ll BiPAP ( 3 ) 
Ll ECMO I bypass ( 5 ) 
3.4 Enteral Feed: u no ( 0 ) I_, yes ( I ) _, 1_1 PO l_l tube feed - device: ___ _ 
3.5 Antibiotic: _ no ( O) _ yes ( I ) - speci fy (drug I route): -------' 
_______ I
______ I
3.6 Steroid: _ no ( O) 
_ yes ( I ) - specify (drug I rou<e): ------~ 
______ I 
3. 7 Antacid: l_l no ( O) l_l yes ( I ) _, specify (drug I route): _____ __ I __ 
______ I__ 
page 2 of I 0 
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Patient Enrolment Number: l_ l_ l_ l_ l Patient's Initials: 1_ 1_ 1_1 
3.8 Anticoagulant: l_ l warfarin ( I ) l_ l heparin ( 2 ) 1_ 1 L:v!WH ( 3) 
I_I ASA(4) I_I NSAJD ( 5 ) l_l tPA ( 6 ) 
1_1 other ( 7) -> speci fY (drug I route): ____ _:I 
3.9 Procoagulant: 1_1 vit K ( I ) 1_1 TXA ( 2 ) 
l_ l DDA VP ( 3) l_ l protamine ( 4 ) 
1_ 1 other ( 5 ) _, speci fY (drug I route): ____ ___: 
3.10 Blood Product: 1_1 PRBC ( I ) l_ l platelets ( 2 ) 
1_1 FFP ( 3 ) 1_1 cryo ( 4 ) l_ l albumin ( 5 ) 
l_l immunoglobulin ( 6 ) _,specifY: _______ _ 
l_l factor concentrate ( 7 ) _, specify: _______ _ 
l_ l cell saver ( 8 ) 
1_ 1 other ( 9) _, specify: _ ______ _ 
3.11 Procedure: l_l surgery ( I ) _, specify: .-:-=--,-::-::--:-----c:---:-::--:--,.--:---:---:-c-:-----
1_ 1 intubation ( 2 ) l_ l NG I OG insertion ( 3 ) f_l catheter ( 4 ) 
1_1 CVL ( 5 ) 1_1 art line ( 6 ) l_ l LP ( 7 ) 
l_l bronchoscopy ( 8) f_ l regional ( 9 ) _, specify: ---- -------
1_1 endoscopy ( 10 ) l_ l other ( II ) _,specify: __________ _ 
3.12 Comple te Blood Count Results : 
Date /Time ( DD / MMM /20 10 at HH:MM ) 
_ 1 _ _ _ I __ 
_ I __ _ I __ _ I __ _ 1 __ 
ar ar ar ar ar ar 
WBC ( X 109 I L ) 
ANC ( xi09 1L ) 
Hemoglobin ( g 1 L ) 
Pla telets ( x 1 o' 1 L ) 
3.13 Coagulation Testing Results 
Da te / Time DD I MMM I 2010 at HH :MM ) 
_1 __ _ I __ , 
_ I __ _ I __ _ I _ _ 
ar ar ar ar ar ar 
PTT (s ) 
Fibrinogen ( g I L ) 
IN R 
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Patient Enrolment Number: l_l_l_l_l Patie~;·s Initials: 1_ 1_ 1_ , 
4. DAY 1: Start at Tadmit 
End at T admit + 24 hours 
= 1_ 1_11_1_ 1_1 121011101 at 1_1_ 1:1_ 1_1 
= I_ U U _ U I 2 I o I I I o I at 1_1_ 1:1_ 1_1 
D D MMM H H M:vl 
4.1 Vital Signs: 
Minimum Maximum 
HR (beats I min) 
Systo lic BP (mmHg) 
RR (b reaths I min) 
O, Sat (%) 
Temp (0 C) 
I I PO ( I) I PR (2) I AX (3) 1 I BL (4) I I PO ( t ll PR (21 I I AX (ll l BL (41 
4.1 Supplemental Oz: l_l no ( 0 ) l_l yes ( I ) __, _ _ % Fi02 or __ L I min 
4.3 Intubated: U no ( 0 ) U yes ( I ) 
Resp. Support: l_ l conventional ( I ) 
1_1 HFOVIHFN ( 4) 
I_I CPAP ( 2 ) I_I BiPAP ( 3 ) 
1_1 ECMO I bypass ( 5 ) 
4.4 Enteral Feed: l_l no ( O) 1_1 yes ( I ) ~ 1_1 PO l_l tube feed ~ device: ___ _ 
4.5 Antibiotic: l_l no ( O) 1_1 yes ( I ) ~ specify (drug I route): ______ _ , 
4.6 Steroid: l_l no ( O) l_l yes ( I ) ~ speci fy (drug I route): _______ ,/ 
_______ .! __ 
4. 7 Antacid: l_l no ( O) l_l yes (I ) --->specify (drug I route): _______ / __ 
_ _ ____ I __ 
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Pa tient Enrolment umber: l_l_l_._l Patient' s Initials: l_l_l_l 
4.8 A nticoagula nt: l_l warfarin ( I ) l_ l heparin ( 2 ) l_ l LMWH ( 3) 
I_I ASA ( 4 ) I_I NSAJD ( 5) l_l tPA ( 6) 
l_l other ( 7) ~ specify (drug I route): _____ .1 __ 
4.9 Procoagulant: 1_ 1 vit K ( I ) 1_ 1 TXA ( 2 ) 
l_l DDA VP ( 3 ) 1__1 protamine ( 4 ) 
l_l other ( 5) ~ specify (drug I route): _____ .1 __ 
4.10 Blood Product: l_l PRBC ( I ) l_ l platelets ( 2 ) 
1_ 1 FFP ( 3 ) 1_1 cryo ( 4 ) l_ l albumin ( 5 ) 
l_l immunoglobulin ( 6) ~ specify: _______ _ 
l_l factor concentrate ( 7 ) ~ specify: ______ _ 
l_l cell saver ( 8 ) 
l_ l other ( 9)---> specify: _______ _ 
4.11 Procedure: l_ l surgery ( I ) ~ specify:-:-=---,--::-=-:-------:--:-::--:-----,---:-:--:-----
1_1 intubation ( 2 ) l_ l NG I OG insertion ( 3) _ catheter ( 4 ) 
l_l CVL ( 5) 1_1 an line ( 6 ) I_ LP ( 7 ) 
l_l bronchoscopy ( 8) l_l regional ( 9 ) ---> specify: -----------
1_ 1 endoscopy ( 10) l_ l other ( II ) ___, specify: __________ _ 
4.12 Complete Blood Count Results: 
Date /Time DD I MMM I 20! 0 at HH:MM) 
_I ____ 1 ____ I__ ---- _1 ____ 1 __ 
at at at at at at 
WBC (X 109 I L) 
ANC (x 109 1 L) 
Hemoglobin ( g 1 L) 
Plate le ts ( x I 09 I L ) 
4.13 Coagula tion Testing Results 
Date/Tim e DD I MMM I 20 l 0at HH :MM ) 
I _ 1 ___ 1 ____ 1 ____ 1 ____ I__ 
at at at at at at 
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Patient Enrolment Number: l_ l_ l_l_l Patient' s Initials: l_ l_ l_ l 
5. DAY 2: Start at T , dmit + 24 hours 
End at T odmit + 48 hours 
= _ 1_11_1_1_1 12 1011101 a/ 1_1_ 1:1_ 1_1 
= _ 1_1 1_1_ 1_1 I 2 I o I I I o I a 1 I_I_ I:I_ U 
D D MMM H H MM 
5.1 Vital Signs: 
Minimum Maximum 
HR (beats I min) 
Systolic BP (mmHg) 
RR (breaths I min) 
o, Sat (%) 
Temp (0 C) 
I PO (Ill PR (211 I IIX (3) 1 BL (4) PO (Ill I PR ('l I I AX(3) 1 I BL (4) 
5.2 Supplemental 0 2: 1_ 1 no ( 0) 1_1 yes ( I ) ---+ _ _ % Fi0 2 or _ _ L I min 
5.3 Intubated: 1_1 no ( 0 ) l_ l yes ( I ) 
Resp. Support: 1_1 conventional ( I ) 
l_ l HFOYIHFJV ( 4 ) 
I_I CPAP(2 ) 1_1 BiPAP ( 3 ) 
l_ l ECMO I bypass ( 5 ) 
5.4 Entera l Feed: i_l no ( O) 
5.5 Antibiotic: l_l no ( O) 
5.6 Steroid: 1_1 no ( O) 
5.7 Antacid: l_l no ( O) 
1_1 yes ( I ) -> 1_1 PO l_l tube feed - device: ___ _ 
1_1 yes ( I ) - specify (drug I route): _ _____ __.cl __ 
_ ___ _ __.cl 
l_l yes ( I ) - specify (drug I route): ___ ___ __.cl __ 
l_l yes ( I ) - specify (drug I route): _ _ _ _ ___ I __ 
_______ I __ 
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Patient Enrolment umber: f_ l_ l_l_l Patient's Initials: l_ l_ l_ l 
5.8 Anticoagulant: 1_1 warfarin ( I ) l_l heparin ( 2 ) 1_ 1 LMWH ( 3 ) 
I_I ASA ( 4) I_I NSA!D ( 5 ) l_l tPA ( 6 ) 
l_l other ( 7)- specifY (drug I route): _____ I __ 
5.9 Procoagulant: 1_1 vit K ( I ) 1_1 TXA ( 2 ) 
l_ l DDA VP ( 3 ) 1_1 protamine ( 4 ) 
1_1 other ( 5) ~specifY (drug I route): ____ _ 
5.10 Blood Product: l_l PRBC ( I ) l_ l platelets ( 2 ) 
1_1 FFP ( 3 ) 1_1 cryo ( 4 ) l_ l albumin ( 5 ) 
l_l immunoglobulin ( 6 ) __, specifY: _______ _ 
1_1 factor concentrate ( 7 ) __, specifY: ______ _ 
l_l cell saver ( 8 ) . 
1_ 1 other ( 9) __, specify : _ ______ _ 
5. 11 Procedure: 1_1 surgery ( I ) __, speci fy: -::----:c-:----:---:--------------
1_1 intubation ( 2 ) 1_1 NG I OG insenion ( 3 ) l_l catheter ( 4 ) 
I_I CVL(5) l_l an line ( 6 ) I_I LP (7) 
1_ 1 bronchoscopy ( 8) 1_ 1 regiona l ( 9 ) __,specifY: __________ _ 
l_ l endoscopy ( I 0 ) 1_ 1 other ( I I ) __, specifY: __________ _ 
5.12 Comp lete Blood Count Results: 
Da te I T ime ( DD I MMM I 20 I 0 at HH:MM ) 
_ , __ 
_ ! __ _ I __ _ 1 __ _! __ _ 1 __ 
at at ar ar ar ar 
WBC c x 1 o' 1 L l 
ANC ( xi09 / L ) 
Hemoglobin ( g 1 L ) 
Platelets ( x to' 1 L ) 
5. 13 Coagulation Testing Results 
Date / Time DD I MMM I 2010 at HH:MM) 
_ / _ _ _ I __ r _I __ _1 __ _ I __ 
ar ar ar ar ar ar 
PTT (s) 
Fibrinoge n (g I L ) 
INR 
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Patient Enrolment Number: 1_ 1_ 1_ 1_ 1 Patient 's Initials: l_ l_l_ l 
6. DAY 3: Start at T ,d.,;t + 48 hours = l_ l_ ll_ l_ l_ l 12' 0 I ! 0 I at 1_ 1_ 1:1_ 1_ 1 
End at T,d,.;, + 72 hours = l_ ._ ll_ l_ l_ l I 2 I 0 I I 0 I at 1_ 1_ 1:1_ 1_ 1 
D D MMM H H MM 
6.1 Vital Signs: 
Minimum Maximum 
HR (beats I min) 
Systolic BP (mmHg) 
RR (breaths I min) 
0 2 Sat (%) 
Temp (0 C) 
I PO ll) I PR 12) AX (3) I BL (41 PO ( l ) l I PR (2 ) AX13) I BL (4) 
6.2 Supplemental 0 2: 1_1 no ( 0 ) l_ l yes ( l ) ---+ __ % Fi02 or _ _ L I min 
6.3 tnntbated: 1_1 no ( 0 ) 1_1 yes ( I ) 
Resp. Support: l_l conventional ( I ) 
1_1 HFOVIHFJV ( 4) 
I_I CPAP ( 2) I_I BiPAP ( 3 ) 
l_ l ECMO I bypass ( 5 ) 
6.4 Enteral Feed: l_l no ( O) 1_1 yes ( I ) ___, 1_1 PO l_l tube feed___, device: _ _ _ 
6.5 Antibiotic: l_l no ( 0 ) l_l yes ( I ) ---> specify (drug I route): ______ ,
6.6 Steroid: l_l no ( 0) l_l yes ( I ) ---> specify (drug / route ): _____ ___:I __ 
6. 7 Antacid: l_l no ( 0) l_ l yes ( I ) ___, specify (drug I route): ______ I __ 
_ _____ I 
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Patient Enrolment Number: l_ l_l_ l_l Patient's Initials: l_ l_ l_ l 
6.8 Anticoagulant: l_ l warfarin ( I ) 1_ 1 heparin ( 2 ) l_ l LMWH ( 3 ) 
I_I ASA ( 4) I_I NSAJ0 ( 5 ) l_l tPA ( 6 ) 
1_1 other ( 7) ~ spec ify (drug I route): _____ / __ 
6.9 Procoagulant: l_ l vit K ( I ) 1_ 1 TXA ( 2 ) 
1_1 DDA VP ( 3 ) l_l protamine ( 4) 
l_l other ( 5) ~ specify (drug I route): _____ / __ 
6.10 Blood Product: l_ l PRBC ( I ) 1_1 platelets ( 2 ) 
1_1 FFP ( 3 ) 1_1 cryo ( 4 ) 1_ 1 albumin ( 5 ) 
l_ l immunoglobulin ( 6) __, specify: _______ _ 
1_1 factor concentrate ( 7 ) __, specify: ___ ___ _ 
l_l cell saver ( 8 ) 
l_l other ( 9) __, specify: _______ _ 
6.11 Procedure: l_ l surgery ( I ) __, specify: ----,---,--:---,--------,- ---------- - -
1_1 intubation ( 2) 1_ 1 NG I OG insertion ( 3) l_ l catheter ( 4 ) 
1_1 CYL ( 5 ) 1_1 art line ( 6 ) 1_1 LP ( 7 ) 
l_ l bronchoscopy ( 8) l_l regional ( 9 ) __, specify: __________ _ 
l_l endoscopy ( 10) 1_ 1 other ( II ) ~specify: -----------
6.12 Complete Blood Count Results: 
Date/Time( DO / MMM / 201 0 a1 HH:MM ) 
_ ! __ _ ! _ _ _ ! __ _ ! _ _ _ I __ _ ! __ 
ar ar ar ar ar ar 
WBC ( x 1 o' 1 L l 
ANC ( xi09 1 L ) 
Hemoglobin (g I L) 
Platelets ( x 1 o' 1 L ) 
6. 13 Coagulation Testing Results 
Date / Time DD / MMM / 2010m HH :MM ) 
_ ! __ _ ! __ I _ ! _ _ _ 1 __ _ , __ 
ar ar ar ar ar ar 
PTT ( s ) 
Fibrinogen ( g I L ) 
INR 
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Patient Enrolment Number: l_l_l_,_l Patient 's Initials: 1_ 1_ 1_ 1 
7. OUTCOMES 
7.1 Patient Disposition: l_l Duration of PICU admission > 72 hours ( I ) 
l_l Discharge from PICU ( 2 ) 
->specify date I time: l_ l_ll_l_l_l 12 10 II I 0 I at 1_1_ 1:1_1_1 
DD MMM HH M M 
1_1 Death in PlCU ( 3 ) 
-.specify date I time: I_I_II_I_U 121 o II I o I at 1_1_ 1:1_1_1 
DD MM:vl HH MM 
7.2 Clinically Significant Bleeding: 1_1 no ( 0 ) 
1_1 yes ( I )-> Complete CRF for each bleeding episode 
When all CRFs for tbis admission are complete : Record dates and times of bleeding events in 
chronological order below. Identify at most one event as tbe Primary Event. 
(Primary Event = first episode of clinically significant bleeding that is not chest tube bleeding from 
a post-op cardiovascular surgery patient.) 
Primary 
Event 
Date I Time of I " event: 
Date I Time of 2"d event: 
U_IU_U 121 0111 01 at U_ILU U 
U _ IU_U 121 0111 01 at U _ I:I_ U U 
Date I Time of 3'd event: 
Date I Time of 4'h event: 
U_IU_U 121011101 at U _ I:I_U U 
1_1_11_1_1_1 12 10111 01 at 1_1_1:1_1_1 u 
DDMMM HHMM 
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Patient Enrolment Number: [_[_[_[_[ Patient's Initials: l_l_l_l 
DEVELOPING A PREDICTION TOOL FOR 
CLINICALLY SIGNIFICANT BLEEDING IN THE PICU 
CASE REPORT FORM- SIGNIFICANT BLEEDING EVENT 
I. BLEEDING EVENT 
1.1 Date and time of bleeding event: [_ [_ [l_ l_ l_ l [ 2 [ 0 [ I I 0 I at [_ [_ [:[_ [_ [ 
D D / MMM / Y YY Y H H M M 
1.2 Detection of bleeding event (specifY site) : 
l_ l Clinical observation:-----------------------
l_l Radiographic observation: ____________________ _ 
1.3 Post-op cardiac surgery AND chest tube bleeding: 1_1 yes l_l no 
1.4 Type of bleeding event (indicate all that apply) : 
I. Blood loss or hematoma formation is thought to have caused any of the following: 
1_1 Death 
l_ l Hypotension (PALS definition) 
l_l Decrease in hemoglobin concentration by at least 20 g I L from baseline 
2. Blood loss or hematoma formation caused significant symptoms or impairment of function. 
1_ 1 Specify:--------------------------
3. Blood loss or hematoma formation resulted in any o f the following interventions: 
[_[ Cardiopulmonary resuscitation 
[_[Surgical management of blood loss (specify below) 
1_ 1 Major revision or reinforcement of a surgical dressing (specify below) 
[_I Procedure, radiography, test, or consult to investigate blood loss (specify below) 
l_l Use of volume expanders in volumes > 20 mL I kg or transfusion ofP RBC (specify below) 
1_1 Use of medication or blood products to control bleeding (specify below) 
I_ [ Cessation of anticoagulation medication (specify below) 
l_ l Delay or avoidance of an essential or urgent procedure or intervention (specijj• below) 
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Patient Enrolment Number: l_ l_l_l_l Patient's Initials: l_ l_ l_ l 
2. V]T AL SIGNS (measurements closest to, bw prior to. clinically significant bleeding event) 
HR: ____ beats I min Systolic BP: ------=--- mmHg RR: breaths I min 
Oz Sat: % Temp: °C l_l PO (I) l_l PR (2) l_l AX (3) 1_1 BL (4) 
3. MANAGEMENT (in the 6 hours following clinically significant bleeding event) 
3.1 Volume Expanders (excluding PRBCs & albumin -list under Blood Products) 
Volume Expander Dose I Volume Date I Time of Administration 
(specify units) D D I MMM !Y E A R H H MM 
u _ lu_u 1210 1110 1 ju_l: l_u 
I_UU_U 1210 1110 1 ju_I:U_I 
3.2 Blood Products 
Blood Product Dose Date I Time of Administration 
(specify units) D D I M M M fY E A R H H M M 
U _l 1_1_1_1 121 o I I I o I j U_l: I_U 
I_ UU_U 121011 10 1 jU_I: I_U 
3.3 Medications (stopped or starred- dose/route/frequency and dare/time ij"starred) 
Medication Dose Route Freq Date I Time of I" Administration 
(units) (units) D D I MMM /Y EAR H H MM 
U _IU_U 12101110 1 U_I:U_I 
l_l started Ll stopped 
I_ U 1_1_ 1_1 12 1 0 I I I o I U _ I:I_U 
l_l started Ll stopped 
3.4 Procedures & Investigations (delayed or perf ormed - dare/rime ij"performed) 
Procedure or Investigation Delayed or Performed Date I Time of Procedure or Investi gation 
D D I MMM !Y E A R H H MM 
l_ l delayed l_l performed I_U 1_1_1_1 121 o I I I o I 1_1_ 1: 1_1_ 1 
l_l delayed l_l performed I_ U 1_1_1_1 121 o I I I o I 1_1_ 1: 1_ 1_1 
l_ l delayed l_l performed I_U U_U 1210 I I I 0 I 1_1_1: 1_1_1 
3.5 Control of Bleeding: l_l yes 1_1 no l_l uncertain 
Comment: ______________________________ __ 
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Appendix 4: Instructions for Case Report Forms for Prospective Study 
DEVELOPING A PREDICTION TOOL FOR 
CLINICALLY SIGNIFICANT BLEEDIN G IN THE PICU 
CASE REPORT FORM - INSTRUCTIONS 
General Instructions 
At the top of each page, enter the Patient's Initials (first, last), and the Patient 
Enrolment Number 
Enter dates in the format DO I MMM I YYYY (i.e. October 22, 1998 is 
22 I OCT I 1998) 
Enter times according to the 24 hour clock in the format HH:MM (i.e. 4 pm is entered 
16:00) 
lf data is not applicable, not known, illegible, or incorrect, enter Nl A. 
To correct an entry, draw a line through the incorrect response, write and circle your 
initials, record the date of the correction, and enter the valid information. See example 
below: 
Blood Pressure: 120 I Ur 93 8 12/Dec/02 
1. DEMOGRAPHICS 
1.2 Take date and time ofPICU admission from nursing admission note. (If time of 
admission is not available there, may take from other sources, such as PICU flow sheet or 
physician order sheet.) 
1.4 Use weight at time of admission to the PICU, taken from nursing admission note. (If 
weight is not recorded on nursing admission note, may take from other sources, such as 
ER documentation, physician order sheet, or PICU flow sheet.) 
1.5 Admission diagnosis is to be determined from documentation at admission (nursing 
note, physician note). Record the reason for admission to PJCU (ex. aspiration 
pneumonia) , not underlying conditions (ex. cerebral palsy). Patients are considered 
"post-op" only if admission to PICU was planned following the OR. Patients who are 
admitted to the PICU because of unexpected perioperative complications should be coded 
according to those complications. 
• trauma = forceful trauma only 
• medical = all other medical conditions, including bums, drowning, hanging 
1.6 For post-op patients only, record estimated blood loss in mL as documented in the 
OR note. For non-surgical patients, record "NIA". 
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2. EXCLUSION CRITERIA 
Determination of whether a patient meets an exclusion criterion is based only on 
information available at time of admission. 
A patient may meet more than one exclusion criterion. If a patient meets any of the 
exclusion criteria, mark as "Excluded", and collect no further data. 
2.1 A patient meets this criterion if admitted to the PICU specifically for control or 
monitoring of bleeding, or of symptoms attributable to bleeding (ex. monitoring for 
neurologic symptoms or increased intracranial pressure due to intracranial hemorrhage). 
Intra-operative bleeding does not meet this criterion, unless it is not controlled at the time 
of admission to PICU. If a patient is admitted to the PICU because of bleeding, specify 
the site. 
2.2 If a patient has a previously diagnosed inherited bleeding disorder, specify the 
disorder. 
2.5 If a patient has a prior inclusion during the study period, record the enrolment number 
of that prior inclusion. 
3. DAY 0 
Record the date and time of admission (Tadmit) and the date and time 24 hours prior to 
admission (Tadmit - 24 hours). This time period is Day 0. 
3.1 Record the maximum and minimum values of all vital signs recorded during Day 0. 
Record site of temperature measurement (PO = oral, PR = rectal, AX = axilla, BL = 
bladder) . 
3.2 If patient received supplemental 0 2 at any time during Day 0, mark "yes" and record 
maximum % 0 2 or Fi02 recorded during Day 0. 
3.3 If patient is intubated at any time during Day 0, mark "yes". Record all forms of 
respiratory support received during Day 0. (Mark all that apply .) 
• 
• 
• 
• 
• 
• 
conventional = conventional ventilation 
CPAP = Continuous Positive Airway Pressure, either by mask or ET tube 
BiPAP = Bimodal Positive Airway Pressure, either by mask or ET tube 
HFOV = High Frequency Oscillator Ventilation 
HFJV = High Frequency Jet Ventilation 
ECMO = Extra-Corporeal Membrane Oxygenation 
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3.4 If patient received any enteral feeding during Day 0, mark "yes" and indicate PO feed 
or indicate tube feed and specify device. Both PO and tube feed may be marked, if both 
types of feeding occurred during Day 0. 
3.5 - 3. 7 If medications were given during Day 0, mark "yes" and indicate generic drug 
name and route of administration. 
3.5 Do not include topical or inhaled antibiotic drugs. 
3.6 Including ranitidine, pantoprazole, omeprazole, lansoprazole, aluminum hydroxide. 
3. 7 Include corticosteroids only. Do not include topical or inhaled steroid drugs. 
3.8 Record all anticoagulant medications given during Day 0. 
• 
• 
• 
• 
• 
heparin = unfractionated heparin (UFH) given as an infusion or in bolus doses 
greater than 10 units I kg. 
LMWH = Enoxaparin, Dalteparin, Tinzaparin, ... 
ASA = aspirin 
NSAID = ibuprofen, ketorolac, indomethacin, celecoxib, ... 
tPA = tissue plasminogen-activator (Alteplase ) . 
3.9 Record all procoagulant medications given during Day 0. Clotting factor 
concentrates should be recorded under "Blood Products" (3 .1 0). 
• 
• 
• 
vit K = vitamin K 
TXA = tranexamic acid (Cyclokapron) 
DDA VP = desmopressin (Octostim) 
3.10 Record all blood products given during Day 0, including blood products used in the 
OR or for cardiopulmonary bypass or ECMO. 
• 
• 
• 
• 
• 
PRBC = packed red blood cells 
FFP =fresh frozen plasma 
cryo = cryoprecipitate platelets 
immunoglobulin = intravenous immunoglobulin (IVIg), varicella immune 
globulin (VZig), anti-D (WinRho), rituximab, .. . 
cell saver = cell saver blood 
3.10 Record all procedures and attempted procedures attempted or performed during Day 
0. Record surgery, even if already recorded 'under Admission Diagnosis (1.5). Do not 
include peripheral IV insertion, suctioning, minor suturing, arterial line removal, central 
venous line removal, extubation, Foley catheter removal, or other minor procedures. 
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• surgery = all surgical procedures, including chest tube insertion 
• intubation = endotracheal intubation 
• NG = nasogastric tube 
• OG = orogastric tube 
• catheter = foley catheter or intermittent urinary catheter insertion 
• CVL = central venous line insertion at any site (IJ or femoral venous line, PICC 
line, dialysis catheter, ... ) 
• art line = arterial line at any site 
• LP = lumbar puncture for any purpose (diagnostic, intrathecal medication 
administration, regional anaesthesia, ... ) 
• regional = regional anaesthesia other than LP 
• endoscopy = upper or lower GI tract endoscopy 
3.11 Record the results of all Complete Blood Counts done during Day 0, and the date 
and time of each test. 
3.12 Record the results of all coagulation testing done during Day 0, and the date and 
time of each test. 
When data collection for Day 0 is completed, indicate at the bottom of Page 3. 
4, 5 & 6 See instructions for Section 3. 
7.0UTCOME 
7.1 Record one and only one disposition for each patient. 
7.2 Indicate whether any episode of clinically significant bleeding (according to the study 
definition) occurred during Days 1, 2 or 3. Complete a bleeding CRF for each episode of 
clinically significant bleeding that occurs during that time period. Record the date and 
time of each clinically significant bleeding event. When the CRF is completed, identify 
at most one event as the patient's primary bleeding event. 
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DEVELOPING A PREDICTION TOOL FOR 
CLINICALLY SIGNIFICANT BLEEDING IN THE PICU 
CASE REPORT FORM- SIGNIFICANT BLEEDING EVENT- INSTRUCTIONS 
General Instructions 
At the top of each page, enter the Patient's Initials (flrst, last), and the Patient 
Enrolment Number 
Enter dates in the format DD I MMM I YYYY (i.e. October 22, 1998 is 
22 I OCT I 1998) 
Enter times according to the 24 hour clock in the format HH:MM (i.e. 4 pm is entered 
16:00) 
If data is not applicable, not known, illegible, or incorrect, enter Nl A. 
To correct an entry, draw a line through the incorrect response, write and circle your 
initials, record the date of the correction, and enter the valid information. See example 
below: 
Blood Pressure: 120 I U- 93 8 12/Dec/02 
1.4 Record date and time of bleeding event. If time of event is not clearly documented, 
record time of documentation. 
1.5 Record mode of detection of bleeding event (clinical or radiographic) and anatomic 
site of bleeding. If bleeding event is detected radiographically, record modality (ex. 
CT, MRI, US) and anatomic site of bleeding. 
1.6 If the patient's reason for admission is Post-Op Cardiac and the bleeding is chest 
tube output, mark "yes"; otherwise mark "no". 
1.7 Record all criteria met by bleeding event (more than one may apply). 
In order for a criterion to be met, it must be the clear opinion of the bedside physician 
that the observed blood loss or hematoma formation is thought to have caused the 
observed effect on the patient or to have resulted in an intervention. 
1. Hypotension is defined according to Pediatric Advanced Life Support criteria: 
-systolic BP < 70 mm Hg for patients less than 1 year of age 
-systolic BP < 70 + 2 x (age in years) mm Hg for patients between 1 and 10 years 
-systolic BP < 90 mmHg for patients > 10 years of age 
In order to meet the criteria for decreased haemoglobin, haemoglobin 
concentration must be decreased by at least 20 g I L from the last haemoglobin 
recorded prior to the onset of bleeding (sections 4.12, 5.12, or 6.12) or, in the 
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case ofbleeding whose onset is prior to any measurement of haemoglobin after 
admission, from the last haemoglobin recorded prior to admission (3.12). 
2. Symptoms or impairment of function may include, but are not limited to: 
- signs or symptoms of respiratory distress from hemothorax 
- signs or symptoms of cardiovascular dysfunction from hemothorax or 
bemomediastinum 
- signs or symptoms of spinal cord compression from paraspinal hemorrhage 
- signs or symptoms of neurologic dysfunction from intracranial hemorrhage 
- loss of visual function due to retinal or intraoccular hemorrhage 
- pain from hemarthrosis or hematoma formation resulting in loss of func tion or 
requiring treatment. 
3. Record interventions if they have occurred in response to bleeding. 
Include revision of central line dressings, arterial line dressings, or surgical 
dressings if the revision was due to bleeding. 
Volume expanders include: pentastarch, 0.9% normal saline (with or without 
dextrose or other additives), Ringer 's lactate, or albumin 5%. 
Include use of medications that do not directly affect hemostasis, if the intent of 
giving the medication is to control bleeding. (ex. H2-blocker or PPI for 
gastrointestinal bleeding, inhaled or topical epinephrine for epistaxis.) 
3 Record the last set of vital signs taken prior to the onset of bleeding. Indicate site of 
temperature measurement. 
4 Record management of bleeding if performed or begun within 6 hours of the 
bleeding event. 
4.1 Record volume expander used, dose used, and date/time of adnunistration. PRBCs 
and albumin 5% should be recorded under Blood Products (3.2). 
4.2 Record any blood product used to replace lost blood (PRBCs) or volume (albumin 
5%), or to control bleeding (platelets, cryoprecipitate, FFP, PCC, human-derived or 
recombinant clotting factor concentrates). 
4.3 Record any medications started or stopped to control bleeding. Record date I time of 
first administration or date I time of stopping. 
4.4 Record procedures or investigations (lab tests or radiographic tests) or consultations 
performed to control bleeding or to investigate bleeding. Record planned procedures 
or interventions that were delayed because of bleeding. 
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4.5 Mark "yes" or "no" if, in the opinion of the bedside physician, bleeding was or was 
not stopped or satisfactorily improved. Otherwise, mark "uncertain". 
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Appendix 5: Prompt Sheet for Bedside Clinicians for Prospective Study 
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Developing a Prediction Tool for 
Clinically Significant Bleeding in the PICU 
Interventions: 
- Use of Volume Expanders or transfusion of PRBC 
- Revision or reinforcement of a Dressing 
- Medication or Blood Products to control bleeding 
- Procedure or Surgery to investigate or control bleeding 
- Heparin, LMWH, or other anticoagulant medication stopped 
- Delay or avoidance of a Procedure or Intervention 
- CPR (cardiopulmonary resuscitation) 
- CT, MRI or other Scan or Test to investigate bleeding 
- Change in Ventilation 
Symptoms: 
- New or changed Respiratory Symptoms 
- Paralysis, Seizures or other neurologic symptoms 
- Loss of Vision 
- Pain resulting in loss of function or requiring treatment 
Effects on Patient: 
- Death 
- Hypotension 
- Decrease in Hemoglobin concentration 
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